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ABSTRACT 
Small molecule screening is commonly used to discover lead compounds for 
drug development, but it can also be a powerful way to identify chemical probes for 
studying biological mechanisms. Our lab uses small molecules to study the mechanisms 
by which the protozoan parasite Toxoplasma gondii infects and replicates within its hosts. 
In this work, we employed a fluorescence-based assay to screen the Medicines for 
Malaria Venture (MMV) Open Access Malaria box for compounds that affect T. gondii 
growth. The box contains 400 previously identified small-molecule inhibitors of the 
related parasite, Plasmodium falciparum. We identified 79 hits, including a 2,4-
diaminoquinazoline (MMV006169; IC50=1.15µM) that strongly inhibits T. gondii 
intracellular replication and invasion with no evidence of toxicity to mammalian cells. 
Extensive structure-activity relationship analyses with T. gondii identified a number of 
analogs with changed potency and altered effects on replication and invasion. These 
structure-activity analyses provided the information necessary to synthesize a bivalent 
chemical inducer of dimerization (CID) containing MMV006169 for use in yeast three-
hybrid experiments. Yeast growth competition assays showed that this CID is capable of 
entering the yeast nucleus, as required for yeast three-hybrid screening. Yeast three-
hybrid was used in a targeted format to test the hypothesis that MMV006169 works by 
inhibiting parasite CDC48, an ATPase involved in trafficking and the degradation of 
misfolded proteins. Large-scale cDNA library screening by yeast three-hybrid suggests 
that the compound may instead be working through inhibition of a host cell target. This 
work has provided insight into how MMV006169 affects the parasite’s lytic cycle and 
generated a testable hypothesis for the biologically relevant target of the compound.  
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 Introduction to Toxoplasma gondii 
1.1.1 The phylum Apicomplexa 
The phylum Apicomplexa is diverse, containing 6,000 known and likely more than 
one million unstudied obligate intracellular protozoans (Adl et al. 2007). These 
organisms are so successful that every vertebrate and invertebrate is parasitized by at 
least one species belonging to this phylum (Portman and Slapeta 2014). Apicomplexans 
are known for their unique invasive stages, which involve an apical complex of secretory 
organelles and cytoskeletal elements (Morrison 2009). This complex is used to aid in the 
entry of host cells, which is essential for at least one stage of each organism’s life cycle.  
The phylum contains a variety of important veterinary pathogens, all of which have 
adopted a parasitic life-style. Neospora caninum has a broad host range; however, it 
causes significant economical loss in the cattle industry as infection results in 
spontaneous abortion of calves. Treatment of neosporosis is limited by the ability to 
detect infection in animals (Dubey et al. 2007). Babesia spp. cause babesiosis, which also 
affects the cattle industry, but can impact humans and other domestic animals as well. 
Recently, efforts to develop treatments for babesiosis have suggested areas for drug 
targeting, but no successful treatments have resulted (Mosqueda et al. 2012).   
Apicomplexans are also an important medical concern for humans. Arguably, the 
most notorious of the Apicomplexan parasites are Plasmodium spp., which cause malaria. 
Between 2000 and 2015, the World Health Organization estimates that of the 218 million 
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people infected by Plasmodium spp., 438,000 lives were lost each year (W.H.O. 2015). 
This is due to the continual ability of the parasite to develop resistance to anti-malarial 
drugs. Cryptosporidium spp. cause the diarrheal disease cryptosporidiosis. Diarrheal 
disease is one of the leading causes of death amongst children under the age of 5, killing 
800,000 children annually (Bhutta and Black 2013).  Despite its clinical importance, the 
drugs available for the treatment of cryptosporidiosis are minimal due to wide efficacy 
ranges in patients (Manjunatha et al. 2016). As a theme, despite the broad host range and 
worldwide prevalence of Apicomplexans, minimal therapeutics are available to treat the 
infections they cause.  
 
1.1.2 Toxoplasma gondii and toxoplasmosis in humans 
Toxoplasma gondii infects nearly 30% of the United States population, and up to 
80% of the population in some parts of the world, causing a condition termed 
toxoplasmosis (Dubey 1994, Remington et al. 1995, Pappas et al. 2009). The life cycle of 
T. gondii has both sexual and asexual phases and involves three infectious forms of the 
organism: sporozoites, tachyzoites, and bradyzoites (Chapter 1 – Figure 1). The sexual 
phase takes place in the definitive host, which can be any domestic or wild feline (Tenter 
et al. 2000). Oocysts containing sporozoites form within the intestines and are shed in 
feline feces. Humans and other intermediate hosts ingest these oocysts, which then 
transform into tachyzoites (Speer et al. 1995). Tachyzoites, the fast replicating asexual 
form of the parasite, are responsible for the lytic cycle (Chapter 1 – Figure 2). The lytic 
cycle begins when a tachyzoite invades a host cell. T. gondii has a broad host-range and 
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is capable of invading any nucleated mammalian cell (Black and Boothroyd 2000). The 
parasite replicates via endodyogeny within a newly formed parasitophorous vacuole. 
Once the host cell is filled with tachyzoites, the parasites secrete perforin-like protein 1 
(TgPLP1), and egress from the host cell (Kafsack et al. 2009). These newly egressed 
tachyzoites then disseminate and invade new host cells. It is the repeated cycling of host 
cell lysis via invasion, replication, and egress that cause noticeable symptoms in humans.  
When the tachyzoite senses stress, such as assault by immune cells or lack of 
nutrients, the parasite will undergo a stage conversion to form the bradyzoite. The 
bradyzoite is the slow-replicating asexual form of the parasite. During stage conversion, 
the parasitophorous vacuole is modified to form a cyst wall and matrix within which the 
bradyzoite resides (Weiss and Kim 2000). The resulting tissue cysts are commonly found 
in the brain, heart, skeletal muscle, and retina of the host. Within these cysts, the parasite 
can lay dormant until the host immune system becomes impaired. At this point the 
bradyzoites convert back to tachyzoites and the lytic cycle begins again.  
Toxoplasmosis can manifest in a variety of ways depending on the immune state 
of the host. The immunocompetent host typically experiences either no symptoms at all, 
or mild flu-like symptoms that are self-limiting and resolve within a few weeks. In the 
immunocompromised individual, toxoplasmosis typically manifests as toxoplasmic 
encephalitis (TE) or ocular toxoplasmosis. Toxoplasmic encephalitis (TE) is commonly 
caused by the reactivation of a chronic T. gondii infection that manifests as hemisensory 
loss, visual field defects, headache, weakness, disorientation, seizures, coma, and death 
(Luft and Remington 1992). TE is of particular importance in AIDS patients as it is often 
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diagnosed before the patient knows of their HIV-status (Porter and Sande 1992). As such, 
it is the most common infection of the central nervous system for those not receiving 
appropriate anti-retrovirals (Walker and Zunt 2005). Ocular toxoplasmosis results from 
the mass infection of the eye tissue and immune cells, resulting in necrosis and retinal 
pigment epithelial cells migrating to, entering the eye, and aiding in phagocytosis (Jones 
et al. 2006). In the United States, ocular toxoplasmosis is considered the most common 
infection of the retina (Jones and Holland 2010). Congenital toxoplasmosis has severe 
effects on neonates, including spontaneous abortion, retinochoroiditis, and cerebral 
calcifications (Dubey and Jones 2008). 
In humans, transmission of infection can take place through carnivorism, a 
fecal-oral route, or congenitally. In 1965, it was shown that the consumption of 
undercooked meat containing tissue cysts resulted in increased levels of T. gondii 
seropositivity in a population of children. The connection between infection and 
carnivorism was later confirmed epidemiologically by looking at seropositivity in areas 
known for consumption of raw meat. It was shown that 80% of the adult population 
tested in Paris was positive for T. gondii specific antibodies (Dubey 2014). The fecal-oral 
route of infection occurs when humans ingest T. gondii oocysts from cat feces. This route 
has been confirmed through experimentation on mice (Dubey et al. 1997). Congenital 
transmission occurs when a pregnant woman becomes infected with T. gondii. During 
pregnancy, the parasite can pass the placental barrier and infect the fetus. The first record 
of a T. gondii-like infection in humans was reported in 1923 in a child born with 
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hydrocephalus (Dubey 2014). The child became blind within three months and died at 11 
months. 
 
1.1.3 Current treatments and limitations 
Despite its prevalence, there are minimal therapeutics available for use in the 
treatment of toxoplasmosis due to specificity of drugs for specific forms and life-cycle 
stages of the parasite as well as high levels of relapse and serious side effects that result 
in the therapeutics’ discontinuation (Tomavo and Boothroyd 1995). The most common 
treatment for infection is a cocktail of pyrimethamine, sulfadiazine, and folinic acid 
(Derouin and Santillana-Hayat 2000). Pyrimethamine is an inhibitor of dihydrofolate 
reductase. While it demonstrates strong anti-Toxoplasma activity, it is associated with 
bone marrow suppression and is potentially teratogenic (van der Ven et al. 1996, 
Montoya and Remington 2008). To avoid the issue of bone marrow suppression, small 
quantities of folinic acid are added to the cocktail. Folinic acid can be used to generate 
purines and pyrimidines when dihydrofolate reductase is inhibited. However, the addition 
of folinic acid has only been marginally successful, as many patients still suffer from 
marrow suppression (Hakes and Armstrong 1983).  
Sulfadiazine works in synergy with pyrimethamine by inhibiting dihydropteroate 
synthase in the same pathway, and is also associated with side effects; sixty percent of 
HIV-patients develop a rash and fever upon sulfadiazine treatment (Porter and Sande 
1992, van der Ven et al. 1996). It should also be noted that some anti-retrovirals, such as 
Zidovudine, reverse the effects of both pyrimethamine and sulfadiazine (Israelski et al. 
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1989). For patients who are unable to tolerate sulfa drugs, sulfadiazine can be replaced 
with clindamycin or azithromycin (Montoya and Liesenfeld 2004, Andrews et al. 2014). 
Women that become infected with T. gondii while pregnant are prescribed a course of 
spiramycin, which has been shown to reduce transmission to the fetus by 60% (Montoya 
and Remington 2008). If congenital transmission has already occurred, the standard 
course of pyrimethamine and sulfadiazine must be administered, as spiramycin cannot 
pass the placental barrier (Montoya and Remington 2008). These present therapeutics are 
insufficient for control of toxoplasmosis not only based on the detrimental side effects, 
but also because they are ineffective against the dormant form of the parasite, the 
bradyzoite.   
 
1.1.4 The model Apicomplexan parasite 
Like other Apicomplexan parasites, T. gondii is a single-celled pathogen that 
requires a host cell for survival. T. gondii is the model organism for its phylum. The 
asexual, pathogenic form of the parasite can be easily maintained by continuous culture 
through a variety of cell lines, such as human foreskin fibroblasts, hTERT, and HeLa 
cells. Parasites can also be preserved indefinitely in liquid nitrogen using DMSO as a 
cryoprotectant (Roos et al. 1994). Methods for continuous culture of other 
Apicomplexans, such as Cryptosporidium spp. are not available, which in turn limits the 
ability to genetically manipulate these organisms. Efficient means of preserving 
Cryptosporidium are also lacking, meaning that fresh oocysts must be isolated regularly 
from animal feces and then prepared for experimental procedures (Gut and Nelson 1999).  
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Animal models for the study of T. gondii infection are plentiful, relevant, and 
used for the study of cerebral, ocular, and congenital toxoplasmosis. The mouse model 
alone has been used to study acute infection, toxoplasmic encephalitis, and 
retinochoroiditis (Dubey 1997, Dubey et al. 1997, Subauste 2012). Other successfully 
utilized animal models include: rat, rabbit, hamster, guinea pig, and primate (Luder et al. 
2014). Plasmodium spp. can be studied in mouse and non-human primate models; 
however, speculation exists as to how relevant these models are (Langhorne et al. 2011). 
For example, in cerebral malaria, it is infected leukocytes that accumulate in the brain of 
mice, and not red blood cells as seen in human infection (Carvalho 2010). Additionally, 
mechanisms for controlling infection in animal models of malaria do not always translate 
to control of human infections (Carvalho 2010).   
The genome of T. gondii has been sequenced and is readily accessible 
(http://toxodb.org/toxo) along with community annotation, gene expression data, ESTs, 
and proteomics data (Gajria et al. 2008). Diverse approaches to genetic manipulation 
have been developed in the last decade that aid in understanding the complex life cycle of 
T. gondii. The development of Δku80 parasite lines, which prevent non-homologous end 
joining, have made the generation of tagged proteins, gene deletions, promoter swapping, 
and allelic replacements more straight-forward (Fox et al. 2009, Huynh and Carruthers 
2009, Sheiner et al. 2011). The recent use of CRISPR technology for genetic 
manipulation of T. gondii has dramatically decreased the time needed to clone complex 
parasite lines and has been used genome-wide to define essential vs. nonessential genes 
(Shen et al. 2014, Sidik et al. 2014, Sidik et al. 2016). Historically, genes have been 
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considered essential only after efforts toward generating a clean deletion have failed. 
Now armed with data from a genome-wide CRISPR screen, researchers can move 
directly towards the generation of parasites with inducible down-regulation or deletion of 
essential genes (Mital et al. 2005, Andenmatten et al. 2012).  Taken together, the ability 
to continuously culture and preserve parasites, relevant animal models, and abundant 
genetic tools make T. gondii the model Apicomplexan parasite.  
 
1.2 T. gondii drug development 
1.2.1 Target- and phenotype-based compound screening 
Small molecule screening is commonly used to discover lead compounds for drug 
development, but it can also be a powerful way to identify chemical probes for studying 
biological mechanisms. A more comprehensive understanding of the mechanisms of 
infection utilized by T. gondii will lead to the generation of drugs with minimal off-target 
effects. Historically, small-molecule screens have taken either a target- or phenotype- 
based approach. Target-based approaches involve the identification of molecules that 
alter the activity of a specific protein target in vitro. This approach comes with the 
advantage of having defined assays for use in screening molecules of interest and for 
confirming putative targets. Knowledge of the target of a compound can also guide in the 
development of meaningful structure activity relationship analyses and toxicology studies 
(Zheng et al. 2013). Disadvantages of this approach involve lack of efficacy of 
compounds in vivo. Screening assays are not always biologically relevant as the molecule 
of interest may not be able to access the particular protein of interest. This approach is 
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also limited by our inability to predict mechanisms of biological compensation. When the 
goal is drug development, target-based approaches can be limiting as potential chemical 
diversity is lost upfront and the ability to discover new targets along the way is reduced. 
Phenotype-based approaches are used to identify molecules that induce a desired 
effect (phenotype) on an entire cell or organism (Kotz 2012). Advantages associated with 
these approaches include knowing that the molecule can enter the cell of interest, the 
screening methodology is biologically relevant, and multiple targets can be modulated at 
once to create a synergistic effect resulting in a desired phenotype. As mentioned above, 
when drug development is a goal, phenotype-based approaches can be associated with 
broad chemical diversity that is not limited to interaction with a specific target. As such, 
this allows for the identification of new/multiple targets throughout the process. 
However, this means that target deconvolution can be more arduous as multiple genes 
must be examined at once. SAR is also more difficult to develop as metabolism and cell-
permeability must be constant considerations (Khurana et al. 2015). The differences 
between target- and phenotype-based approaches can be likened to reverse and forward 
genetics respectively. In a reverse genetics approach the goal is to identify a phenotype 
associated with a gene disruption, whereas in forward genetics screens one identifies a 
gene responsible for a specific phenotype. 
Both target- and phenotype-based screens have been used to study T. gondii. In 
2010, it was shown that bumped kinase inhibitors (BKIs) can inhibit TgCDPK1 (Murphy 
et al. 2010, Ojo et al. 2010). Using structural and sequence-based analysis of the ATP-
binding site of mammalian kinases versus TgCPDK1, it was found that TgCDPK1 has a 
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unique glycine gate-keeper residue in its active site. Three novel BKIs were synthesized 
to improve the specificity of compound binding. Two of these BKIs (NA-PP2, and NM-
PP1) were specific, potent inhibitors of TgCDPK1 as determined by a radiometric 
scintillation assay, an ATP consumption assay, and co-crystallization.  
In 2011, a Hybrid Structure Based method was used to identify small molecules 
capable of disrupting the interaction between Myosin A (TgMyoA) and Myosin Light 
Chain-1 (TgMLC1) (Kortagere et al. 2011). The approach involved structural modeling 
of the TgMyoA-TgMLC1 interaction, custom design of a pharmacophore that could 
disrupt this interaction, computational compound library screening, and identification of 
the compounds that best match the designed pharmacophore. The identified compounds 
were then screened against T. gondii for defects in invasion, and one compound was 
chosen as a potential lead for drug development. At this point, no new drugs have 
resulted from either study.  
While the aforementioned target-based approaches for isolation of lead compounds 
was useful to better aid in the understanding of general parasite biology, the majority of 
small-molecule screens against T. gondii are phenotype-based. These small-molecule 
screens have been completed using diverse compound libraries containing varied classes 
of compounds or targeted libraries containing only specific types of compounds. 
Complete compound libraries screened against T. gondii have been examined to identify 
inhibitors of invasion. Carey et al. screened 12,160 molecules and identified 24 inhibitors 
and 6 enhancers of invasion (Carey et al. 2004). In addition to invasion, these compounds 
were found to have varying effects on microneme secretion, conoid extension, and 
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motility. One compound from this screen, tachypleginA, was shown to target TgMLC1 
by formation of an adduct on C58, which decreases the parasites myosin motor activity 
(Heaslip et al. 2010, Leung et al. 2014). This compound, however, does have additional 
targets and was shown to have cytotoxic effects after 24 hours.  The second study looking 
for compounds impacting parasite invasion identified WRR-086 (Hall et al. 2011). WRR-
086 modifies C127 in the gene encoding DJ-1. This mutation results in the inability of the 
parasite to attach to host cells and successfully invade. While both of these screens 
helped to better understand parasite invasion and other associated processes, no 
successful drugs have been developed as a result of these studies.  
 Kamau et al. screened a targeted library of 527 kinase inhibitors for an effect on T. 
gondii growth (Kamau et al. 2012). Fourteen different compounds were identified as 
altering (increasing or decreasing) parasite growth kinetics and having varying effects on 
motility and parasite morphology. To date, the targets of these compounds in the parasite 
are unknown. Recently, a drug-repurposing screen was performed using the Tocriscreen 
Total Library of compounds (1,120), which identified tamoxifen and pimozide as 
potential anti-T. gondii drugs (Dittmar et al. 2016). While drug repurposing has the 
potential to quickly identify new therapeutics, the authors acknowledge that target 
confirmation is necessary, since off-target effects may be playing a role in parasite 
inhibition. It should now be apparent that simply identifying a compound of interest is 
not enough to lead to the development of a successful drug. The process requires 
compound optimization and a straightforward approach to target identification. 
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1.2.2 SAR studies 
Both target- and phenotype-based approaches to drug development require 
extensive compound optimization based on the ligand of choice through a process termed 
structure-activity relationship (SAR) analyses. SAR analyses can be used to reveal how 
biological processes are related to chemical structures. In one sense, they can be used to 
improve small molecules of interest by strategically adding and removing portions of a 
compound to increase its affinity for a single protein target. In cell culture, one is 
working with a homogenous system of a single cell type where a drug may only bind to 
one specific target. Once administered to an intact organism, the potential for secondary 
and tertiary targets becomes possible. For example, in T. gondii, Compound 2 is an anti-
parasitic compound effective against multiple targets, including TgCDPK1, TgPKG, and 
TgCK1α (Donald et al. 2006). Recently, it was shown that this compound has a fourth 
target; TgBRADIN (Odell et al. 2015). To prevent compound promiscuity, SAR can 
identify structural analogs with increased compound specificity. For example, the 5-
aminopyrazole-4-carboxamide chemical scaffold has been shown to be an effective 
inhibitor of TgCDPK1. The C-3 substitution of a 2-cyclopropoxy group on this chemical 
scaffold resulted in a compound with increased solubility and potency against TgCDPK1 
(0.22 µM to 0.089 µM), and was able to better eliminate T. gondii from the brain, spleen, 
and peritoneal fluid (Huang et al. 2015). SAR was also used to determine novel substrates 
of uracil phosphoribosyltransferase. The study screened 100 different analogs of uracil 
and identified 5 novel substrates with increased affinity for the enzyme (Iltzsch and 
Tankersley 1994).  
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In addition to identifying and increasing potency for protein-binding partners, 
SAR is pivotal in ensuring that small molecules can traverse necessary biological 
membranes and as such work the same way in vivo as they do in vitro (Lien 1981). A 
common limitation of drug development is getting the intact small molecule of interest 
within proximity of its intended target. A potent compound may appear to function 
perfectly in vitro, but fail when applied to an in vivo model. This lack of an effect may be 
due to the drug being degraded to a non-functional form by the pH or enzymes present in 
the gastrointestinal tract (Sousa et al. 2008). In addition to host enzymes that may 
degrade the drug to a useless product, a score of enzymes provided by the gut microflora 
may contribute to degradation. The microbiota mainly digest drugs via hydrolytic and 
reductive reactions that result in non-polar byproducts (Sousa et al. 2008). These 
byproducts themselves may be useless or, due to their non-polar nature, associate with 
fatty tissue and be sequestered from the bloodstream preventing delivery of the drug to its 
site of action (Qureshi 2010). In addition to storage in adipose tissue, degraded drug 
products can also be secreted through urine without ever being absorbed (Qureshi 2010).  
Altering a compound’s lipophilicity can help to ensure it will reach an environment of 
interest. For example, if one wishes to design a drug that can pass biological membranes 
and find a receptor, the lipophilicity should be increased (Lien 1981). Conversely, if a 
one wishes to prevent a compound from passing the blood-brain barrier, the lipophilicity 
should be reduced (Lee 1991).  
SAR is also useful in making small molecules of interest more “drug-like”. 
Lipinski’s rule of five has been considered the standard when designing a membrane 
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permeable, easily absorbed drug. The rules include having a molecular weight less than 
500 Daltons, a partition coefficient of less than 5 (see above discussion for optimizing 
lipophilicity), fewer than 5 hydrogen bond donors, and fewer than 10 hydrogen bond 
acceptors (Leeson 2012). By optimizing these qualities, SAR can make a compound 
easier to synthesize and alter its pharmacokinetic properties, such that the compound has 
an increased likelihood of working in vivo. 
 
1.2.3 Mechanisms for Target Identification  
Once a compound of interest has been selected and optimized, one must next 
identify the biologically relevant target(s) of the molecule to truly understand any 
phenotypes resulting from compound treatment. A variety of approaches for small-
molecule target identification exist, both direct and indirect, each with its own set of 
limitations and advantages. Direct approaches to target identification look specifically 
at small molecule-target interactions, while indirect approaches look at protein or gene 
expression profiling, morphological changes, and sensitivity of the target to the drug to 
determine the target. The most common direct approach to target identification is 
through affinity chromatography. This technique involves the compound of interest 
being derivatized to a solid matrix. One successful use of this technique involved the 
derivatization of an analog of trapoxin, K-trap, to a resin matrix. Mammalian cell 
extract was run over the column, followed by washing, and two distinct compound 
interacting partners were identified (Taunton et al. 1996). In 1999, epoxomicin was 
derivatized to biotin at the amino terminus and incubated with cell lysate. The resulting 
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mixture was probed by western blot with streptavidin-horseradish peroxidase, and three 
catalytic components of the 20s proteasome were identified (Meng et al. 1999).  
A phage display approach to target identification involves the biotinylation of 
the compound, its immobilization on a streptavidin coated plate, and screening of phage 
libraries. The libraries are panned across the plate and any interacting proteins remain 
on the plate after washing. The phage is then eluted, phagemid is isolated, and the gene 
encoding the target can be sequenced. This technique was successfully used to show 
that UQCRB is the target of terpestacin (Jung et al. 2010). Along similar lines, protein 
microarrays can be used to identify compound targets. Tagged versions of the 
compound are flowed over protein microarrays, washed to remove non-specific 
interactions, and the array imaged to determine where the tagged molecule resides. This 
approach was validated by showing direct biotin-streptavidin, anti-digoxigen antibody-
digoxigen, and FKBP12-AP1497 binding (MacBeath and Schreiber 2000).    
These direct techniques are limited by the inherent nature of the compound-
target interaction. The interaction needs to be high affinity to survive the vigorous 
washing steps involved and/or the target needs to be abundant enough to be visualized 
on and isolated from a gel for follow-up identification (Burdine and Kodadek 2004). 
These approaches also require extensive SAR analyses to ensure the molecule is linked 
to the matrix/affinity-label in a manner that still allows it to interact with its unknown 
target. 
Drug Affinity Responsive Target Stability (DARTS) is an indirect approach to 
target identification that does not rely on derivatization of the small molecule (Lomenick 
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et al. 2009, Pai et al. 2015). The technique relies on a small molecule stabilizing or 
protecting its target from proteolysis. In the proof of principle experiment, human Jurkat 
cells were exposed to didemnin B, a known inhibitor of EF-1α, and thermolysin (Crews 
et al. 1994). Samples were run on SDS-PAGE gels, coomassie stained, and a single 
enriched band (didemnin B and thermolysin treated) was confirmed to be that of EF-1α 
(Lomenick et al. 2009). This approach is useful in that it can be used in any cell or tissue 
type, is not enzyme specific, and has a simple readout. However, as with the 
aforementioned affinity-based approaches, DARTS is limited by the strength of the small 
molecule-target interaction.  
Genomics-based approaches to target identification involve screening the 
expression level of genes in the presence and absence of a compound. Scherf et al. 
analyzed the expression levels of 8,000 genes in untreated human cancer cell lines and 
then treated those cancer cell lines with over 1,400 compounds of interest (Scherf et al. 
2000). Correlations between compound treatments and changes in gene expression were 
then mapped, enabling target identification to be performed. An alternate approach is 
whole-genome mutagenesis, where one treats mutagenized cells with a compound of 
interest and selects for resistant organisms. This has proven useful in the study of T. 
gondii where the n-ethyl-n-nitrosourea (ENU) mutagenized genome of resistant parasites 
can then be sequenced and the relevant target confirmed (Pfefferkorn and Pfefferkorn 
1979, Gubbels et al. 2008, Coleman and Gubbels 2012, Farrell et al. 2014). 
Metabolomics- and proteomics-based approaches are similar in that the data set is 
analyzed in the absence and presence of the drug, and changes in metabolite or protein 
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expression are noted for further hypothesis-driven work (Watkins et al. 2002, Plavec et 
al. 2004). Similar to the DARTS approach discussed above, Thermal Proteome Profiling 
(TPP) looks at the ability of a small molecule to stabilize, or prevent the denaturation of, 
a protein during heating (Savitski et al. 2014). TPP was validated by using human K562 
chronic myeloid leukemia cells heated to different temperatures in the presence and 
absence of kinase inhibitors (staurosporine or GSK3182571). The resulting cellular 
supernatants are analyzed by SDS-PAGE and mass spectrometry to determine which 
proteins demonstrate a thermal shift and as such interact with the small molecule 
(Franken et al. 2015).  
The aforementioned indirect approaches to target identification are 
advantageous in that they require no additional chemical derivations be performed on the 
molecule of interest. However, they are limited by the fact that they rarely identify a 
single target; rather they reveal only a focused area of cellular physiology in which the 
molecule is involved. This becomes further complicated when a compound is 
promiscuous and interacts with multiple targets. In most cases, these indirect approaches 
must then be followed by direct hypothesis-driven approaches.  
 
1.3 Yeast three-hybrid 
1.3.1 Applications 
Genetically modified yeast can be used in an alternate approach to small-molecule 
target identification. The system was originally described as yeast two-hybrid, in which 
the Saccharomyces cerevisiae GAL4 transcription factor was split into two functional 
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domains, the DNA-binding domain (DBD) and activation domain (AD). The Gal4-DBD 
is incapable of activating transcription unless physically associated with an activation 
domain. The DBD was fused to SNF1, a serine-threonine-specific kinase, while the AD 
was fused to SNF4, a protein known to associate with SNF1, and is required for it to 
function maximally. The yeast genome was also engineered to encode lacZ under the 
control of the GAL1 (galactose inducible) promoter. Using yeast expressing both halves 
of the transcription factor, it was shown that when SNF1 and SNF4 associate, the 
transcription factor is reconstituted and can thus up-regulate the expression of the lacZ 
reporter gene by interacting with the upstream activating sequence (Fields and Song 
1989). Based on this proof of principle experiment, it was suggested that any two proteins 
(a bait and prey) could be fused to either half of a split transcription factor and be used to 
demonstrate direct protein-protein interactions.  
The yeast-two hybrid system was modified over time to include components from 
additional proteins such as the DBD of the E. coli repressor LexA, the AD from the “acid 
blob” protein B42, and the AD of the herpes virus protein VP16 (Triezenberg et al. 1988, 
Ruden et al. 1991, Golemis and Brent 1992, Gyuris et al. 1993, Vojtek et al. 1993). 
Together, the yeast two-hybrid system has been successful in the identification of direct 
protein-protein interactions for proteins as small as 8-10 amino acids and as large at 755 
amino acids (Heery et al. 1997, Young 1998). The reporter genes used in yeast two-
hybrid systems have been broadened beyond the use of lacZ. Common “primary 
reporters” include genes required for the synthesis of amino acids. The use of these 
synthetic genes makes it easy to measure reporter activation by plating yeast on selective 
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media. The most commonly used reporters include LEU2 and HIS3, which are required 
for successful yeast growth on media lacking leucine and histidine respectively (Chien et 
al. 1991, Gyuris et al. 1993). Colorimetric reporters, such as lacZ and MEL1 can be used 
as “secondary reporters” (Aho et al. 1997). Other variations to the yeast two-hybrid 
system include the fusion of entire cDNA libraries to the AD in place of a single protein, 
which allows for high-throughput screening for protein interacting partners.  
The concept of including a linker molecule in the system led to the development 
of the yeast three-hybrid methodology (Chapter 1 – Figure 3). First implemented in 1996, 
the yeast three-hybrid was used to detect protein-RNA and protein-small molecule 
interactions (Licitra and Liu 1996, SenGupta et al. 1996). The system is fundamentally 
the same as the yeast two-hybrid, where the activation of a transcriptional reporter is 
dependent upon the functional assembly of a transcription factor. Instead of looking at the 
direct interaction of two fusion proteins, the system now depends upon the interaction of 
each end of a bivalent molecule with those fusion proteins. This bivalent molecule was 
named the chemical inducer of dimerization (CID) since it is necessary to dimerize 
proteins. Originally, a dexamethasone-FK506-based CID was used in conjunction with 
fusion proteins expressing the rat glucocorticoid receptor fused to the LexA-DBD and 
human FKBP12 fused to the B42-AD. Upon interaction of the CID with each fusion 
protein, the lacZ gene was activated and was detected using media containing 5-bromo-4-
chloro-indolyl-β-D-galactopyranoside (Licitra and Liu 1996). The same CID was then 
used to determine if yeast three-hybrid could be used to identify receptors for a ligand. 
They screened a Jurkat cell cDNA library fused to the B42-AD for targets of FK506 and 
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isolated two variants of FKBP12, indicating that the system was capable of identifying 
known interacting partners of FK506. Yeast three-hybrid methodology has been used to 
identify a variety of compound-protein interactions, but it was not until 2002 that the use 
of a GAL4-based system was implemented (Henthorn et al. 2002). Since large number of 
GAL4-AD containing cDNA libraries are available, this allows for the screening of small 
molecules against a variety of organisms and tissue sources. Odell et al. reported the first 
use of the yeast three-hybrid methodology in the study of a pathogen in 2015. A CID was 
generated linking Compound 2, an imidazopyridine known to inhibit the T. gondii lytic 
cycle, to methotrexate. Using this CID and a T. gondii cDNA library, it was found that 
Compound 2 inhibits TgBRADIN (Odell et al. 2015).  
An alternate approach to yeast three-hybrid was developed using a SNAP-tag 
system (Chidley et al. 2011).  The CID is comprised of the small molecule of interest 
linked to an O6-benzylguanine (BG) derivative. This BG derivative can covalently bind 
to a SNAP-tagged DBD. This generates a stable anchor between the CID and DBD. Upon 
association of the target protein with the small molecule, reporter genes are expressed as 
previously described. Using this approach, eight different CIDs were generated 
containing methotrexate, dasatinib, purvanol b, erlotinib, atorvastatin, sulfasalazine, 
furosemide, and indomethacin. These CIDs were screened against different human cDNA 
libraries where both known and novel targets were identified. This approach is useful in 
that the same CID (BG linked to small molecule) can be coupled to glutathione S-
transferase (GST). Affinity chromatography can be performed using glutathione 
sepharose beads in the presence and absence of GST-tagged CID exposed to cellular 
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lysate. The subsequent interacting/target protein can be eluted and identified by western 
blot or mass spectrometry.  
 
1.3.2 CID Development 
In order to perform a successful yeast three-hybrid screen, one must first obtain an 
optimally constructed CID. A typical CID contains a small molecule of interest, a linker 
unit, and a compound with a known binding partner (e.g., dexamethasone) (Chapter 1 - 
Figure 3). In an attempt to make the generation of CIDs more straightforward, systems 
were designed to work with commercially available components. The first successful 
CID generated from these components contained dexamethasone fused to methotrexate, 
which was successful in the dimerization of the glucocorticoid receptor with 
dihydrofolate reductase (DHFR) (Lin et al. 2000, Baker et al. 2003). A major 
consideration when synthesizing CIDs is how to derivatize each component into one 
molecule such that it still retains the ability to bind to its target. For example, one must be 
certain that methotrexate is properly attached to a small molecule of interest such that it 
can still interact with DHFR. Walton et al. performed extensive SAR studies on 
methotrexate and was able to identify a functional position for attachment to other 
molecules (Walton et al. 2009). Thorough SAR studies must also be performed to 
determine how to attach the small molecule of interest to the other end of the linker. 
Another important property of CIDs is the length of the linker unit present 
between methotrexate and the small molecule of interest. Initially, it was believed that the 
chemical nature and length of CIDs had no impact on the ability to bridge proteins. This 
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was based on the use of three CIDs containing chemically distinct linker units of varying 
lengths. Each of these CIDs was capable of bridging FK506 with FKBP12 (Spencer et al. 
1993). In the context of yeast three-hybrid, the impact of CID structure was first analyzed 
in 1997, when four FK1012-based CIDs with linkers of varying length and composition 
were compared with regards to reporter activation. It was determined that, while all the 
CIDs were functional, dramatic differences in potency exist, suggesting that linker length 
and composition is important for optimal transcriptional activation (Amara et al. 1997). 
In contrast, a similar study was performed with respect to lacZ transcriptional activation 
using four different dexamethasone-methotrexate CIDs. The linkers were all generated 
using similar chemistry and were comprised of varying length methylene subunits. While 
the shortest linker unit (3 methylene subunits) was incapable of activating transcription, 
the authors concluded that there was otherwise no correlation between CID size and 
transcriptional activation (Abida et al. 2002).  Discrepancies between studies may be due 
to differences in affinity between CIDs and target proteins, steric hindrance created by 
the proteins, or the distance required between proteins for optimal binding (Tran et al. 
2013).  
CID development is also rate-limited by the number of synthetic steps necessary 
to achieve the desired chemical structure. It was reported that generation of a single CID 
containing a standard polyethylene glycol (PEG) linker took 21 synthetic steps, 7 of 
which were required only to generate the linker unit (Odell et al. 2015). In an attempt to 
streamline CID development, the concept of modular CID synthesis was proposed 
(Chapter 1 – Figure 4). This approach involves the coupling of methotrexate to an azide 
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and the small molecule of interest to an alkyne. Each of these components could be 
coupled to varying lengths of PEG linker and then attached via click chemistry to create a 
triazole containing CID (Chapter 1 – Figure 4) (Tran et al. 2013). This new approach has 
streamlined CID development, making it easier to develop families of CIDs 
simultaneously. 
 
1.3.3 False negatives and positives 
Yeast three-hybrid technology is limited by the presence of false negatives and 
positives in the system. A false negative is defined as a small molecule-protein 
interaction, which cannot be detected by the chosen screening method. These false 
negatives can be membrane bound proteins, which are not detectable in standard yeast 
three-hybrid experiments that require the target protein to be shuttled into the yeast 
nucleus. To avoid this issue, the yeast three-hybrid strategy must be chosen carefully to 
ensure that the desired proteome is being probed (Bruckner et al. 2009). Steric hindrance 
is a common cause of false negatives. Fusing a cDNA library or hypothesized protein 
target to a transcription factor may prevent the protein conformation needed to interact 
with the small molecule of interest. Troubleshooting can be done with hypothesized 
targets by swapping the half of the transcription factor fused to the bait with that of the 
prey or by fusing the transcription factor to the other terminus (e.g., fusing the 
transcription factor at the carboxy- instead of amino-terminus). Additionally, expressing 
these fusion proteins in yeast may result in changes in or the absence of necessary post-
translational modifications to the target protein that prevent small molecule-protein 
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interactions from occurring as they would in the target organism. To avoid this issue, the 
transcription factor fusion proteins can be co-expressed in the presence of those enzymes 
needed for a given post-translational modification (Osborne et al. 1996). Lastly, an 
inherent issue in the reproducibility of library screens leads to a large number of false 
negatives. Yeast two-hybrid system experiments performed under identical conditions 
have been shown to be only 30% reproducible and identify only 12.5% of known targets 
(Ito et al. 2001). This means that a number of true positive interactions are often excluded 
based on the inability to repeat a given result.  
False positive results are obtained when the activation of reporter genes happens 
in the absence of a direct small molecule-target protein interaction. The fact that 
transcription factor fusion proteins are being overexpressed in a non-native environment 
(e.g., the yeast nucleus) can contribute to this problem. As a result, yeast proteins can 
interact with the small molecule and parts of the fusion protein resulting in reporter 
activation. Since these proteins are not found in the target organism, they are called false 
positives. Lastly, “sticky” or misfolded proteins can result in non-specific interactions 
with the bait and prey and result in reporter activation. One way to minimize the presence 
of false positives in yeast “n”-hybrid systems is to implement a negative selection step 
(Chapter 1 – Figure 5). This selection requires the presence of the URA3 reporter gene 
under the control of an inducible promoter matching that of the other reporters used in the 
yeast “n”-hybrid screen. An aliquot of pre-transformed yeast (containing bait and prey) is 
plated on media containing 5-fluoroorotic acid (5-FOA). 5-FOA converts precursor 
molecules in the uracil biosynthetic pathway to a toxic product (5-FUMP). This means 
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that anything expressing URA3 in the absence of a functional transcription factor will be 
killed. Yeast that survives this selection is pooled and used in conjunction with CID to 
perform full-scale library screens (Chidley et al. 2011). While this can significantly 
reduce the number of false positive interactions seen, it likely will not eliminate them all.  
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Chapter 1 – Figure 1: Life cycle of T. gondii 
T. gondii oocysts shed in feline feces (1) are consumed by and encyst in intermediate 
hosts (2, 3, 5 and 6). Humans become infected through the consumption of tainted food 
or water (7), blood transfusions (8), changing kitty litter (7), or through consumption of 
undercooked meat containing tissue cysts (6). Once in the human, the parasite can infect 
neonates (9, 11) or become cysts in the brain and skeletal muscle (10). Image courtesy of 
the CDC; http://www.cdc.gov/parasites/toxoplasmosis/biology.html.  
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Chapter 1 – Figure 2: Lytic cycle of T. gondii 
T. gondii tachyzoites form an intimate attachment with a host cell and invade through the 
formation of a moving junction. Within a parasitophorous vacuole, parasites replicate via 
endodyogeny. Parasites egress from the vacuole through a myosin-driven process 
coupled with perforin-like protein secretion.  
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Chapter 1 – Figure 3: Schematic of yeast three-hybrid system 
Yeast three-hybrid systems rely on the separation of a transcription factor into its DNA-
binding (DBD) and activation (AD) domains. These domains are expressed as fusion 
proteins to DHFR and a cDNA library protein, respectively. Upon addition of a CID 
composed of methotrexate, a linker, and a small molecule of interest (above), the 
transcription factor will assemble and activate the expression of reporter genes. 
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Chapter 1 – Figure 4: A modular approach to CID Synthesis 
Schematic of modular CID synthesis with compound of interest shown in pink, 
methotrexate in blue, and components of the linker shown in green. From (Tran et al. 
2013). Copyright © 2013, Tran et al; licensee MDPI, Basel, Switzerland. Used under 
the terms of the Creative Commons Attribution license 3.0. 
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Chapter 1 – Figure 5: 5-FOA-based negative selection strategy 
Non-self-activating clones do not activate the expression of URA3 (OMP decarboxylase). 
5-FOA is metabolized to 5-FOMP, which is non-toxic, allowing yeast cell survival. Self-
activating clones, which induce the expression of URA3, convert 5-FOA to toxic 5-
FUMP, resulting in cell death. 5-FOA: 5-fluoroorotic acid; 5-FOMP: 5-fluoroorotidine 
monophosphate; 5-FUMP: 5-fluorouridine monophosphate. Adapted with permission 
from Macmillan Publishers Ltd: Nature Chemical Biology (Chidley et al. 2011), 
copyright © 2011. 
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CHAPTER 2: SMALL-MOLECULE SCREEN AND STRUCTURE ACTIVITY 
RELATIONSHIPS IDENTIFIES 2,4 DIAMINOQUINAZOLINE AS INHIBITOR 
OF T. GONDII AND C. PARVUM 
 
[N.B. Some material from this chapter has been published in the following form: 
 Bessoff, K., T. Spangenberg, J. E. Foderaro, R. S. Jumani, G. E. Ward and C. D. Huston 
(2014). "Identification of Cryptosporidium parvum active chemical series by repurposing 
the open access malaria box." Antimicrob Agents Chemother 58(5): 2731-2739] 
 
2.1 Introduction 
Toxoplasma gondii, the causative agent of toxoplasmosis, is a highly infectious 
protozoan parasite infecting roughly 30% of the United States population and up to 80% 
of the population in some parts of the world (Dubey 1994, Remington et al. 1995, Pappas 
et al. 2009). T. gondii is a member of the phylum Apicomplexa, which contains many 
important human (e.g., Plasmodium and Cryptosporidium spp.) and veterinary (e.g., 
Neospora and Babesia spp.) protozoan pathogens. T. gondii has a multi-stage life cycle 
involving sexual reproduction in the definitive feline host, and asexual reproduction in a 
number of intermediate hosts. In the human host, an acute infection involves the fast 
replicating tachyzoite stage invading, replicating in, and egressing from host cells 
resulting in cell lysis. The host immune system controls these acute infections by forcing 
the parasite to differentiate into the slow replicating bradyzoite. As a result the infection 
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becomes chronic with bradyzoites forming tissue cysts, primarily in the brain, cardiac, 
and skeletal muscle.  
As with other Apicomplexan parasites, there is a need for additional drugs to 
treat toxoplasmosis. Current therapeutics available for the treatment of T. gondii include a 
cocktail of pyrimethamine, sulfadiazine, and folinic acid (Derouin and Santillana-Hayat 
2000). In some cases sulfadiazine can be replaced with clindamycin or azithromycin 
(Montoya and Liesenfeld 2004, Andrews et al. 2014). However, due to the high incidence 
of relapse and occurrence of side effects, these treatments often must be discontinued 
(Porter and Sande 1992, Tomavo and Boothroyd 1995, van der Ven et al. 1996). To date, 
no effective therapeutics are available for the treatment of chronic T. gondii infections. In 
order to develop better drugs against T. gondii, a deeper understanding of parasite 
biology is necessary.  
The Medicines for Malaria Venture (MMV) is a partnership founded to reduce 
the global burden of malaria by aiding in the development of affordable anti-malarial 
therapeutics. Recently, the MMV presented the Open Access Malaria box, a battery of 
200 drug-like and 200 probe-like commercially available small molecule inhibitors. 
These inhibitors were selected from >19,000 compounds originally identified as 
inhibitors of erythrocyte-stage P. falciparum by the screening efforts of 
GlaxoSmithKline, St. Jude Children’s Research Hospital, and Novartis (Gamo et al. 
2010, Guiguemde et al. 2010, Meister et al. 2011, Spangenberg et al. 2013). The MMV 
Open Access Malaria box has been useful in identifying inhibitors of a variety of 
apicomplexans including P. falciparum, Cryptosporidium parvum, T. gondii, and 
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Theileria annulata (Spangenberg et al. 2013, Bessoff et al. 2014, Boyom et al. 2014, 
Hostettler et al. 2016, Van Voorhis et al. 2016).  
In the present study, we screen the MMV Open Access Malaria box to identify 
inhibitors of T. gondii growth. We focus on MMV006169, which inhibits the growth of 
both T. gondii and C. parvum (Bessoff et al. 2014), and find that it also reduces T. gondii 
invasion and replication, but has no effect on motility. Extensive structure activity 
relationship (SAR) analyses of MMV006169 against both T. gondii and C. parvum are 
reported. Lastly, we use yeast three-hybrid technology to test the hypothesis that 
MMV006169 interacts with TgCDC48 (TgCDC48Cy and TgCDC48Ap, respectively), 
and find no evidence of a direct interaction with either.  
 
2.2 Materials and Methods 
2.2.1 Host cell and parasite culture 
Human foreskin fibroblasts (HFFs) (ATCC CRL-1643) were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10 units/mL 
penicillin G sodium salt, 10 units/mL streptomycin sulfate, 10 mM HEPES, pH 7.2, and 
containing 1% heat-inactivated fetal bovine serum (FBS; 1% DMEM) at 37°C, 5% CO2, 
and constant humidity. Cells were split by the addition of trypsin to release host cells 
from the surface of tissue culture flasks and resuspended in DMEM supplemented as 
above but containing 10% FBS (10%DMEM) as described in (Roos et al. 1994) . 
 T. gondii 2F1 YFP2 tachyzoites (Gubbels et al. 2003), kindly provided by Dr. 
Marc-Jan Gubbels, were serially passaged in confluent monolayers of HFFs. 
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2.2.2 YFP-based growth assay 
Growth of T. gondii strain 2F1 YFP2 parasites expressing yellow fluorescent 
protein (YFP) was monitored as previously described (Gubbels et al. 2003) with a few 
modifications. Briefly, parasites and HFFs were cultured in HyClone DMEM/high 
modified medium lacking phenol red (Thermo Fisher Scientific), supplemented with 10 
units/mL penicillin, 10 units/mL streptomycin sulfate, 10 mM HEPES, pH 7.2, and 
containing 1 or 10% v/v fetal bovine serum (FBS). Approximately 5x103 HFFs (in 50 µL 
medium containing 10% v/v FBS) were seeded into each well of a Special Optics 
black/clear 384-well tissue culture-treated plate (BD Falcon) and grown at 37°C, 5% 
CO2, and constant humidity. Upon confluence, culture medium was removed, wells were 
washed once with culture medium containing 1% v/v FBS, and then replaced with 30 µL 
of the same medium. Parasites were harvested by syringe release, passed through a 3-µm 
Nuclepore filter (Whatman, Piscataway, NJ) to eliminate host cell debris, and gently 
pelleted (1,100 x g, 4 minutes). The resulting parasite pellets were resuspended in 
medium supplemented with 1% v/v FBS, counted, and diluted to 1x105 parasites/mL. 
Each well of the assay plate was inoculated with 20 µL (2000) parasites, followed by the 
addition of test compounds serially diluted from DMSO stocks in culture medium 
supplemented with 1% v/v FBS. Assay plates were in incubated at 37°C in 5% CO2, and 
fluorescence was read daily for 8 days from the bottom of the plate with the lid in place 
using a Synergy 2 microplate reader (BioTek, Winooski, VT). The program was 
optimized to a set sensitivity of 60, with excitation filter of 485/20 and emission filter of 
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528/20. Positive controls were included in all assays (typically pyrimethamine). The IC50 
of each compound was determined as described previously (Bessoff et al. 2014). 
 
2.2.3 MMV Malaria box screening 
The 400 small-molecules included in the MMV box (Spangenberg et al. 2013) 
were diluted to 1.67 mM in DMSO and consolidated into two V-bottom polypropylene 
384-well plates (Whatman, Piscataway, NJ). Vehicle (DMSO) and positive control 
(pyrimethamine) wells were scattered throughout the plate. Prior to each use these plates 
were warmed to 37°C and centrifuged to ensure compounds were concentrated at the 
bottom of each well. Compounds were transferred to the wells of HFF seeded Special 
Optics black/clear 384-well tissue culture-treated plates (BD Falcon) using a 384 solid 
pin Multi-Blot replicator tool (V&P Scientific) as previously described (Bessoff et al. 
2014). Compounds were screened using the YFP-based growth assay at a final 
concentration of 2.3 µM in duplicate. Upon completion of the eight-day assay, each well 
was visually screened for evidence of compound cytotoxicity, precipitation, and parasite 
plaque formation. 
 
2.2.4 ATPase assay 
 To assess host cell viability in the presence of compounds of interest we 
performed ATPase assays using the CellTiter-Glo Luminescent Cell Viability Assay 
according to manufacturer's instructions (Promega, Madison, WI). Briefly, Special Optics 
white 384-well tissue culture-treated plates (Corning, Corning, NY) were seeded with 
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5x103 HFFs (in 50 µL medium containing 10% v/v FBS) and grown at 37°C, 5% CO2, 
and constant humidity. Upon confluence, culture medium was removed and replaced with 
30 µL of 1% DMEM. Compounds diluted in DMEM were added to each well to a final 
concentration of 10 µM (5 µL). Positive and negative controls (sodium azide 143 mM 
final and DMSO) were included in each plate. Plates were incubated at 37°C, 5% CO2, 
and constant humidity. After 24 hours, an equal volume of CellTiter-Glo Reagent was 
added to each well. Plates were agitated by shaking for 2 minutes, followed by 
stabilization of the luminescence accomplished by incubating the plate for 10 minutes at 
room temperature. Luminescence was recorded using a Synergy 2 microplate reader 
(BioTek, Winooski, VT) and presented as relative luminescence units (RLU). 
 
2.2.5 Replication assay 
HFFs were grown to confluence on 12 mm circular coverslips in 12-well plates. 
2F1 YFP2 parasites were harvested by syringe release, passed through a 3-µm Nuclepore 
filter (Whatman, Piscataway, NJ) to eliminate host cell debris, and gently pelleted (1,100 
x g, 4 minutes). 4x105 parasites were added to each coverslip in the presence of each 
compound of interest. Coverslips were removed 36 hours post infection and incubated in 
fixative solution (1X PBS + 4% v/v paraformaldehyde) for 20 minutes, permeabilized 
(1X PBS + 0.25% v/v Triton X-100) for 15 minutes, and blocked for 30 minutes in 1X 
PBS + 1% w/v bovine serum albumin. Coverslips were incubated in mouse anti-IMC1 
(mAb 45.36, 0.75µg/mL) at a 1:1000 dilution in block solution for 1 hour and then goat 
anti-mouse IgG conjugated to Alexa 546 (Invitrogen, 2mg/mL) at a 1:500 dilution for 30 
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minutes. Coverslips were then sealed to the surface of glass slides using nail polish. One 
hundred fields of each sample were counted blindly at 100X on a Nikon Eclipse TE300 
epifluorescence microscope.   
 
2.2.6 Invasion assay 
Invasion assays were performed in a manner similar to that previously described 
(Carey et al. 2004). Harvested 2F1 YFP2 tachyzoites were counted and 5x105 parasites 
were added to confluent HFFs grown on 12 mm circular coverslips in 12-well plates in 
the presence of each compound of interest (or DMSO). Plates were left at room 
temperature for 15 minutes to allow the parasites to settle and were then shifted to 37°C 
for 1 hour. Loosely attached parasites were washed away with 1x PBS and each coverslip 
was then prepared for immunofluorescence as described above with the following 
modifications. Cells were fixed in 1X PBS + 3.1% v/v paraformaldehyde, 0.06% 
glutaraldehyde. Fixed coverslips were stained with mouse anti-SAG1 (DG52) diluted 
1:200 for 30 minutes and then goat anti-mouse IgG conjugated to Alexa 546 (Invitrogen, 
2 mg/mL) at a 1:500 dilution for 30 minutes. Coverslips were then permeabilized and 
stained again with mouse anti-SAG1 (DG52) diluted 1:200 for 30 minutes and then goat 
anti-mouse IgG conjugated to Alexa 488 (Invitrogen, 2 mg/mL) at a 1:500 dilution for 30 
minutes. All intracellular parasites (green) in 100 fields were counted blindly at 100X on 
a Nikon Eclipse TE300 epifluorescence microscope.   
 
2.2.7 Two-Dimensional trail assay 
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Trail assays were performed similarly to that described previously (Dobrowolski 
and Sibley 1996, Carey et al. 2004). Briefly, wells of a Special Optics black/clear 384-
well tissue culture-treated plate (BD Falcon) were coated with Cell-Tak per 
manufacturer’s instructions (Corning, Corning, NY). NaHCO3 (100 mM, pH 8.0) was 
used for adsorption. Wells were washed twice with PBS prior to parasite loading. 2F1 
YFP2 parasites were harvested, counted, and diluted (in 10mM Hepes buffered Hank’s 
Buffered Saline Solution (HBSS) containing 1% v/v dialyzed FBS) to 1.5x107 
parasites/mL. Compounds were diluted in Hepes buffered HBSS. To each well 
containing Cell-Tak, 20 µL of parasites was mixed with 30 µL of each compound and 
incubated for 15 minutes at room temperature followed by 30 minutes at 37°C. The 
contents of each well were aspirated, washed, and replaced with 2.5% paraformaldehyde 
for 10 minutes. After fixation, wells were treated with 1x PBS + 0.5% w/v bovine serum 
albumin for 15 minutes.  Parasites were stained with mouse anti-SAG1 (DG52) diluted 
1:500 for 15 minutes and then goat anti-mouse IgG conjugated to Alexa 488 (Invitrogen, 
2 mg/mL) at a 1:500 dilution for 15 minutes. A thin layer of overlay (1X PBS containing 
75% glycerol and 0.05% NaN3) was used to keep wells from drying out. The number of 
trails per field was scored blindly across each well in duplicate.  
 
2.2.8 Construction of pGADCDC48Ap and pGADCDC48Cy 
Plasmid construction was performed using restriction enzymes and Phusion high 
fidelity polymerase purchased from New England BioLabs (Ipswitch, MA). Primers used 
were synthesized by Sigma Aldrich (The Woodlands, TX). To construct 
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pGADCDC48Ap, the plasmid pGADT7 (Clontech Laboratories, Mountain View, CA) 
was digested with SacI and NdeI. CDC48Ap was amplified from RH ΔhxgprtΔku80 
cDNA using primers 1 and 2. Purified digested plasmid and CDC48Ap PCR product 
were co-transformed into competent AH109 yeast as previously described (Gietz and 
Schiestl 2007). Transformants were plated on yeast drop out plates (SC +Glu –leu) and 
incubated at 30°C for 48 hours. The resulting plasmid was screened by restriction digest 
and DNA sequencing using primers 3-7 (Chapter 2 – Table 5). pGADCDC48Cy was 
cloned as described above using primers 8-13 (Chapter 2 – Table 5).  
 
2.2.9 CID competition assay 
 CID competition assays begin with yeast co-transformed with a plasmid 
encoding E. coli dihydrofolate reductase fused to the Gal4 DNA-binding domain 
(pGBKeDHFR, cloned by Anahi Odell, unpublished) and a plasmid encoding the Gal4 
activation domain fused to TgCPDK1. A single colony was grown at 30°C overnight in 3 
mL of synthetic complete liquid media (SC +Glu –trp –leu). The next morning, 4 mL SC 
+Glu –trp –leu was inoculated with 200 µL of the turbid yeast culture and incubated for 4 
hours with shaking. Log phase cells (determined by OD600) were diluted to 2x105 
cells/mL and 25 µL was used to inoculate each test well in a 96-well plate (BD Falcon) 
containing 125 µL SC +Glu –trp –leu –his. CID7 (1.5 µL of 2.5 mM or DMSO) and 3-
AT (1.5 µL of 50 mM) was added to each well.  To half of the experimental samples, 1 
µL of 40 mM Mtx-MMV006169 was added. Plates were parafilmed and incubated with 
shaking (200 rpm) at 30°C. With the lid in place, the OD600 for each well was recorded 
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from the bottom of the plate using a Synergy 2 microplate reader (BioTek, Winooski, 
VT). Plates were read daily and the assay was terminated when robust growth was 
observed in positive control wells that lack Mtx-MMV006169.  
 
2.2.10 Targeted yeast three-hybrid liquid assay 
 To perform targeted yeast three-hybrid assays a plasmid containing the 
hypothesized compound target (pGADCDC48Ap or pGADCDC48Cy) and a plasmid 
encoding E. coli dihydrofolate reductase fused to the Gal4 DNA-binding domain 
(pGBKeDHFR) was co-transformed into competent AH109 yeast cells, plated on yeast 
drop out plates (SC +Glu –trp –leu) and incubated at 30°C for 48 hours. A single colony 
of the resulting transformants was grown overnight in 3 mL of synthetic complete liquid 
media (SC +Glu –trp –leu). The next morning, 200 µL of turbid yeast culture was used to 
inoculate 4 mL of SC +Glu –trp –leu and incubated for 4 hours. Log phase cells 
(determined by OD600) were counted and diluted to 2x105 cells/mL and 25 µL was used 
to inoculate each test well in a 96-well plate (BD Falcon) containing 125 µL SC +Glu –
trp –leu –his. CID (1.5 µL of 2.5 mM or DMSO) and 3-AT (1.5 µL of 50 mM) were 
added to test wells. As a negative control, 1.5 µL DMSO and 1.5 µL 3-AT were added to 
wells containing 150 µL of media alone. Yeast expressing pGBKeDHFR and a plasmid 
encoding the Gal4 activation domain fused to TgCPDK1 were used as a positive control 
(125 µL media, 1.5 µL 2.5 mM CID7, 1.5 µL 50 mM 3-AT, and 25 µL yeast). Plates were 
parafilmed and incubated with shaking (200 rpm) at 30°C. With the lid in place, the 
OD600 for each well was recorded from the bottom of the plate using a Synergy 2 
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microplate reader (BioTek, Winooski, VT). Plates were read daily and the assay was 
terminated when robust growth was observed in positive control wells.  
 
2.3 Results 
2.3.1 MMV box screen identifies 79 inhibitors of T. gondii growth 
Given that many proteins and biochemical processes are conserved between P. 
falciparum and T. gondii, we hypothesized that a high percentage of the molecules 
included in the MMV Malaria box as inhibitors of P. falciparum would also function as 
T. gondii inhibitors. We screened the MMV Malaria box in duplicate against T. gondii 
using a YFP-based growth assay (Gubbels et al. 2003). For simplicity and to aid in the 
identification of potent compounds of interest, all 400 compounds in the box were added 
to assay plates using a pin transfer device that deposits compound at a final concentration 
of 2.3 µM (Bessoff et al. 2014).  Upon completion of the 8-day growth assay, monolayers 
were visually scored for evidence of compound toxicity, insolubility, and host cell 
integrity. Seventy-nine compounds, a 19.8% hit rate, were found to alter T. gondii growth 
kinetics at 2.3 µM in both replicates (Chapter 2 – Table 1).  By comparing these screen 
results with data previously generated against C. parvum (Bessoff et al. 2014) and by 
closely examining each chemical scaffold for synthetic accessibility, we were able to 
narrow our focus down to 5 compounds of interest: MMV000720, MMV403679, 
MMV001246, MMV000642, and MMV006169 (Chapter 2 – Table 2). Each of these 
compounds was reordered and screened for an effect on T. gondii growth at 11 different 
concentrations to extrapolate IC50 values (Chapter 2 – Table 2).  From these 5 
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compounds, we chose MMV006169 as our focus based on potency against T. gondii 
(1.15 µM), a similar IC50 against C. parvum (1.50 µM) (Bessoff et al. 2014), ease of 
chemical synthesis, and the availability of analogs commercially (Chapter 2 – Figure 1). 
MMV006169 showed no evidence of host cell toxicity based on visual examination of 
wells during each growth assay (maximum 18 µM) or by ATPase assay (10 µM) (Chapter 
2 – Figure 2).  
  
2.3.2 MMV006169 inhibits T. gondii invasion, but not motility 
The lytic cycle of T. gondii in human cells is a complex, multi-step process (see 
Chapter 1). In order to better understand how MMV006169 inhibits T. gondii growth, we 
tested individual steps of this lytic cycle to determine if the compound could inhibit 
invasion, replication, and/or motility.  Parasite invasion is dependent on its ability to glide 
along, attach to, and enter host cells, so in a sense, motility is essential for invasion 
(Black and Boothroyd 2000, Carey et al. 2004).  We tested the parasite’s ability to invade 
host cells using a two-color immunofluorescence invasion assay where the surface 
antigen, TgSAG1, of intracellular parasites is stained green, and extracellular parasites 
are stained red (Carey et al. 2004). Upon quantification of the number of intracellular 
parasites per field we found that MMV006169 did inhibit invasion at 10 µM (green, 
p≤0.05), but not the lower concentration tested (5 µM, red) compared to vehicle control 
(blue) (Chapter 2 – Figure 3A).  
Parasite motility was analyzed by 2D trail assay, which exploits the fact that 
Apicomplexans deposit surface antigen “trails” as they glide along a substrate 
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(Dobrowolski and Sibley 1996). As with the invasion assay, the surface antigen, 
TgSAG1, can be stained on a given substrate and these trails can be quantified. No 
significant difference in the mean number of trails per field was seen at 5 (red) or 10 µM 
(green) compared to a vehicle control (blue) (Chapter 2 – Figure 3B).  
 
2.3.3 MMV006169 inhibits T. gondii replication 
 T. gondii replication occurs via a process termed endodyogeny, where two 
daughter parasites form within the mother (Sheffield and Melton 1968). The mother’s 
inner membrane complex, a series of flattened vesicles underlying the plasma membrane, 
serves as the scaffold for new daughters (Hu et al. 2002). During cell division, the 
mother’s organelles are partitioned between the newly formed daughters and any 
remnants are left in a small residual body (Hu et al. 2002). Replication can be quantified 
by recording the number (e.g., 2, 4, 8, and 16 or more) of surface stained parasites present 
in individual parasitophorous vacuoles over time. Parasites exposed to MMV006169 (5 
µM, red, Chapter 2 – Figure 3C) for 36 hours, show a severe replication defect where 
98% of the vacuoles seen contain only two parasites.  
 
2.3.4 Structure activity relationship analyses 
In order to better understand how MMV006169 inhibits T. gondii replication 
and invasion, we expanded our compound library to include structural analogs containing 
a conserved 2,4-diaminoquinazoline scaffold (Chapter 2 – Figure 1C, red). We 
hypothesized that structural changes to MMV006169 might differentially affect 
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replication and invasion. To test this, we purchased 26 and synthesized 48 analogs 
containing the 2,4-diaminoquinazoline scaffold, screened each of them by growth assay, 
and calculated associated IC50 values. The majority of screened analogs (n=68) ranged in 
potency from 0.26 – 11.54 µM, while 6 analogs were found to have IC50 values outside 
the range tested (Chapter 2 – Table 3).  These compounds were screened in parallel 
against C. parvum for inhibitory effects on growth ((Bessoff et al. 2014) and Rajiv 
Jumani, personal communication). To differentiate between effects on invasion and 
replication, we chose 11 molecules with different potencies against T. gondii and C. 
parvum, as well as analogs with major changes to the chemical backbone (Chapter 2 – 
Table 4). None of the analogs chosen have toxic effects against the host cells after 24 
hours (Chapter 2 – Figure 4). By changing the chemical structure of these compounds we 
are able to determine which parts of the compound are essential for an effect on 
replication and/or invasion.  
The majority of structural analogs examined inhibit T. gondii replication in a 
manner similar to the parent molecule (Chapter 2 – Figure 5). However, treatment with 
either C-6 or C-10 resulted in only partial inhibition of replication. Here, we define 
partial inhibition of replication as having 40% (or more) of vacuoles containing 4-8 
parasites per vacuole, with no vacuoles containing 16 or more parasites. C-11 has only a 
minor effect on replication, where fewer vacuoles (19% vs. 56%) containing 16 or more 
parasites were seen in comparison with the vehicle control. This analog has three 
modifications: a trifluoromethyl group on position 3 of R1, a methoxy group on position 8 
of R1, and a methoxy group on position 4 of R3. C-4 contains the same modifications on 
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R1 and R3, but still inhibits replication. FT14.025.2, not included in the replication 
analyses, contains both the modifications on R1 and R2, and can still inhibit T. gondii 
growth (Chapter 2 - Table 3). This suggests that the combination of methoxy groups on 
R2 and R3 prevent the small molecule from interacting with its target(s). All other analogs 
tested appear to inhibit replication, suggesting that having more than 2 modifications (C-
6 and C-11) to the structure prevent the analog from properly associating with its 
replication associated target(s) and that hindrance of the amine on R3 (C-10) leads to only 
partial inhibition (an isopropylamine is sufficient).  
To analyze the effects of structural analogs on invasion we chose to use a subset 
of 5 analogs that included structural modifications to each of three portions of the 
molecule (R1, R2, and R3) and also included representatives of each of the three 
replication phenotypes described above: inhibition, partial inhibition, and no effect. 
These assays suggest that only single modifications made on R1 and R3 retain the ability 
to inhibit invasion (Chapter 2 – Figure 6 and Chapter 2 – Table 4). Specifically, the single 
modification of R1 on C-1 with a single trifluoromethyl group on position 3 and the 
single modification of R3 on C-7 with a methoxy group on position 2, both result in 
inhibition of invasion. More than one modification of R1 results in invasion levels equal 
to that of the DMSO control (C-5, C-6). C-11, with modifications to R1, R2, and R3 
(discussed above), yield invasion levels equivalent to that of DMSO. C-11 does not 
inhibit T. gondii growth at concentrations up to 18 µM, this correlates with the lack of an 
effect seen in both invasion and replication assays. Similarly, C-11 does not inhibit C. 
parvum growth at concentrations up to 10 µM. 
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In our replication assays, we only scored vacuoles containing two or more 
parasites (i.e., vacuoles in which at least one round of replication had taken place) and the 
data are expressed as the percentage of the total vacuoles containing at least two 
parasites. However, we noted that the total number of two-parasite containing vacuoles 
was low in all compound-treated samples. This led us to ask if the small number of two-
parasite containing vacuoles in these samples was due to inhibition of invasion or the 
inability to initiate endodyogeny. To test this, we measured the total number of one- and 
two-parasite containing vacuoles 36 hours post-infection using the differential two-color 
staining strategy typically used in invasion assays (Carey et al. 2004). We found that for 
those analogs that caused the most severe invasion defect in a 60-minute invasion assay 
(p≤0.0001, C-1 and C-7, Chapter 2 – Figure 6), the number of two-parasite containing 
vacuoles was considerably lower after 36 hours than one-parasite vacuoles (Chapter 2 – 
Figure 7). This suggests that while the parasites are able to eventually invade, they are 
not successfully initiating endodyogeny.  
 
2.3.5 CDC48 does not interact with Mtx-MMV006169 
 Structure-based searches aimed toward the identification of the target(s) of 
MMV006169 identified the inhibitor N2N4-dibenzylquinazoline-2,4-diamine (DBeQ) as a 
previously characterized structural analog of MMV006169  (Bessoff et al. 2014). DBeQ 
is a potent, reversible inhibitor of an AAA ATPase (ATPase associated with diverse 
cellular activities) known as p97 (or CDC48) that is involved in protein trafficking and 
the degradation of misfolded proteins (Chou et al. 2011). Previous work suggested that 
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p97 functions in the P. falciparum endoplasmic reticulum-associated degradation 
(ERAD) pathway and showed that treatment of parasites with DBeQ inhibits growth 
(Harbut et al. 2012). We reordered and tested DBeQ for an effect on T. gondii growth and 
found it to inhibit growth with similar potency (1.42 µM) to MMV006169, but having 
lost potency against C. parvum (4.73 µM) (Bessoff et al. 2014) (Chapter 2 – Table 3, 
OSSL_324373). Interestingly, T. gondii has two isoforms of CDC48 (TgCDC48Cy and 
TgCDC48Ap) with three different cellular localizations (TgCDC48Cy to the plasma 
membrane and endoplasmic reticulum; TgCDC48Ap to the apicoplast) (Agrawal et al. 
2009). While CDC48 proteins are highly conserved, these isoforms are of divergent 
phylogenetic evolution. Consistent with vertical evolution, TgCDC48Cy exists in a clade 
with homologs found in chromalveolates, while TgCDC48Ap groups with proteins found 
in organisms that contain secondary plastids (Agrawal et al. 2009). Based on differences 
in cellular localization, the function of these proteins is thought to differ. TgCDC48Cy 
has been hypothesized to aid in the trafficking of proteins to the proteasome, and also in 
helping to bring proteins into the parasite from the host cell. TgCDC48Ap may play a 
role in trafficking nuclear-encoded proteins into the apicoplast (Agrawal et al. 2009). 
More studies are needed to confirm these hypotheses. Protein alignments comparing each 
T. gondii isoform (TgCDC48Cy: TGME49_273090 and TgCDC48Ap: 
TgME49_321640) with the P. falciparum ortholog (PlasmoDB: PF3D7_1133400) reveal 
76 and 37% identity, respectively. This led us to hypothesize that MMV006169 may be 
working through inhibition of TgCDC48Cy and perhaps also TgCDC48Ap.  
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 To test this hypothesis we utilized a targeted yeast three-hybrid system. The 
system allows us to directly test small molecule-protein interactions by expressing bait 
and prey proteins fused to each half (DNA-binding domain (DBD) and activation domain 
(AD)) of a split transcription factor (Licitra and Liu 1996, Henthorn et al. 2002, Baker et 
al. 2003, Chidley et al. 2011, Odell et al. 2015). A bridging molecule, termed the 
chemical inducer of dimerization (CID), containing methotrexate, linker, and a small 
molecule of interest brings the bait/prey fusion proteins together in a functional ternary 
complex, which can activate the expression of different reporter genes (Chapter 2 – 
Figure 8A). We expressed the DBD of the GAL4 transcription factor as a fusion with 
dihydrofolate reductase (DHFR), and the AD as a fusion with each isoform of T. gondii 
CDC48. The CID, Mtx-MMV006169, was synthesized by our collaborators at the 
University of St. Andrews (Drs. Fanny Tran and Nicholas Westwood) using the 
previously described SAR analysis to determine the optimal position for linker 
attachment (Chapter 2 – Figure 8B). CID competition assays show that Mtx-
MMV006169 can enter yeast and compete for binding with a positive control CID 
(Chapter 2 – Figure 9). Using this functional CID and the CDC48 fusion proteins, we 
found no direct interaction between either isoform, suggesting that CDC48 is not the 
target of MMV006169 in T. gondii (Chapter 2 – Figure 10 and 11).  
 
2.4 Discussion 
 While the identification of lead compounds is of vital importance for drug 
development, if the protein targets of these drugs are not fully understood the potential 
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for unexplained side-effects increases. Since the parasite lytic cycle is necessary for 
proliferation and viability, understanding the cellular machinery involved in growth is 
vital to the development of more useful anti-parasitics. The MMV Open Access Malaria 
box presented itself as a unique tool for the identification of potential anti-Toxoplasma 
compounds since the compounds included in the Malaria box have already been shown to 
inhibit erythrocyte-stage P. falciparum (Gamo et al. 2010, Guiguemde et al. 2010, 
Meister et al. 2011, Spangenberg et al. 2013). Additionally, a number of the targets of 
these molecules have already been characterized in other systems, helping to focus future 
target identification efforts. 
We have screened the 400 small molecules available in the MMV Open Access 
Malaria box using a high-throughput YFP-based growth assay for inhibition of T. gondii 
(Gubbels et al. 2003, Bessoff et al. 2014). Screening this collection at a single 
concentration resulted in the identification of 79 potential inhibitors for further analysis. 
This represents a 19.8% hit rate in our hands. Further examination of the synthetic 
accessibility of these analogs and comparison of potencies against other apicomplexans 
led us to focus on one compound, MMV006169. MMV006169 is a potent (1.15 µM) 
inhibitor of T. gondii growth that we also showed inhibits both replication and invasion. 
The compound contains a 2,4-diaminoquinazoline scaffold, and while MMV006169 has a 
similar potency in T. gondii and C. parvum, other compounds containing this scaffold 
were previously found have different potencies between the two organisms. It has been 
suggested that these differences could be consequences of parasite divergence. For 
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example, C. parvum lacks an apicoplast and thus uses different biochemical mechanisms 
to generate isoprenoids than T. gondii (Bessoff et al. 2014).  
Further structure activity relationship analyses confirmed the lack of correlation 
between T. gondii and C. parvum IC50s for different analogs. However, these SAR 
analyses provided further insight into how the molecule may be working in T. gondii. 
Single modifications of R1 and R3 result in molecules sufficient to inhibit invasion and 
replication, while these effects are lost if more than one modification of R1 is present. 
Modifications to all three ring structures are not tolerated to maintain inhibition of 
invasion and replication. Interestingly, preliminary invasion assays with additional 
structural analogs suggest the substitution of methylamines to either end of the compound 
(R3 on C-10 and R1 on C-2, data not shown) result in enhancement of invasion. This 
suggests that the availability of the free, unhindered amine groups plays a role in 
enhancement of invasion. This requires further analysis and confirmation using the more 
sensitive laser-scanning cytometry method of quantifying parasite invasion (Mital et al. 
2006). However, The presence of a conserved aromatic amine playing a role in the 
enhancement of invasion was previously reported on a group of substituted 
chloroisocoumarins (Child et al. 2013). Synthesis of an analog of these enhancers lacking 
the amine resulted in lack of enhancement. These chloroisocoumarins were shown to 
target TgPPT1, but lack of an impact on replication and structural differences led us to 
believe that MMV006169 is likely working on another target. Another enhancer of 
invasion found in a large-scale compound screen also contains an unhindered aromatic 
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amine (Carey et al. 2004). Further analysis of the role of this functional group on 
enhancement of invasion is needed.  
A compound containing the 2,4-diaminoquinazoline scaffold, was previously 
presented as being a novel inhibitor of T. gondii motility, but not invasion (Kamau et al. 
2012). This is an interesting phenotype since the machinery necessary for T. gondii 
motility is also essential for parasite invasion. We resynthesized this molecule (Chapter 2 
– Table 3, FT14.116.2) to look more critically at both processes. The assays used by 
Kamau et al., were very general and only looked at changes in parasite trails and overall 
invasion after one hour. There is a possibility that the parasites are actually moving, just 
not in the canonical fashion observed by trail assays. We performed invasion assays using 
two concentrations of compound (5 and 10 µM) and found an invasion defect at the 
higher concentration of 10 µM (data not shown). Trail assays reveal that compound 
treated parasites were still able to move (i.e., generate trails) comparable to those of the 
DMSO control (data not shown). These discrepancies could be due to compound freeze 
thaws or impure commercially provided compound in their hands.  
We used the previously discussed SAR analyses to generate a CID for use in 
yeast three-hybrid experiments. We chose EN01.065 (C-7) as the starting point for 
synthesis and generated a CID capable of passing the yeast cell membrane as 
demonstrated by CID competition assay. Using this CID, neither isoform of CDC48 
induced the expression of reporter genes, suggesting there is no direct interaction 
between CDC48 and MMV006169. However, there are some limitations to the yeast 
three-hybrid system that may generate false negative results. First, the expression of T. 
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gondii genes in yeast may result in misfolded proteins. If the protein is not in its native 
confirmation, it will not interact with the small molecule correctly, and thus not induce 
reporter genes. It is also possible that the T. gondii CDC48 proteins are not being made or 
are being made and then degraded. Since the proteins have been cloned into the yeast 
vector with an HA-tag, their presence can be tested by western blot. Localization of the 
protein can also be examined using immunofluorescence. This would allow the 
confirmation of the nuclear localization of the protein, but it will not confirm 
functionality of the protein. If the protein is not functional, it may not be able to interact 
with MMV006169 to produce reporter activation. To test the functionality of the T. 
gondii isoforms in S. cerevisiae we could complement CDC48 deficient yeast with each 
of the T. gondii isoforms. S. cerevisiae CDC48 mutants are characterized by the presence 
of apoptotic markers and cell cycle arrest where large budded cells appear with the 
nucleus located in the neck between the mother and the daughter cell (Moir et al. 1982, 
Frohlich et al. 1991, Madeo et al. 1997). Should complementation rescue the cell cycle or 
apoptotic phenotypes, and yeast three-hybrid experiments fail, then we would move on to 
other target identification strategies for MMV006169. However, should complementation 
experiments fail, we could only conclude that the isoforms do not function analogously to 
that of yeast proteins in that specific environment. Confirmation of functionality would 
then require the expression of these proteins recombinantly and testing for the ability for 
the ATPase to function with more specifically designed assays.  
Steric hindrance can also cause problems. In a yeast three-hybrid system prey 
proteins are fused to a transcription factor. It could be that generating fusions with the 
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amino terminus of each gene prevent proper small molecule binding. To counter this, the 
transcription factor could be fused to the carboxy terminus instead. CDC48 is thought to 
associate with Der1, a pore involved in the ERAD pathway (Agrawal et al. 2009). It is 
possible that CDC48 needs to be associated with Der1 for proper folding to occur, and as 
such will not occur in yeast. CDC48 orthologs are commonly transmembrane proteins, 
but there is no evidence of transmembrane domains in either T. gondii isoform.  Lastly, 
addition of the methotrexate/linker portion of the CID to MMV006169 may preclude the 
compound from properly interacting with its target. Further analyses of these possibilities 
will be the subject of future studies. Nonetheless, this work has provided extensive SAR 
analyses of MMV006169, which may contribute to future, lead compound development 
and outlined the impact of a subset of analogs on invasion and replication.  
 
 
 54 
Chapter 2 – Table 1: Summary of MMV box hits against T. gondii 
 
MMV box compounds found to inhibit T. gondii growth at 2.3 µM after two biological 
replicates. Smiles, source data, set, and plate locations provided by MMV. 
 
HEOS	COMPOUND	ID Smiles Source Set
PLATE	
March2012
WELL	
March2012
PLATE	
May2012
WELL	
May2012
MMV666601 CCOC(=O)C1=C(N=C2SC(=Cc3cc(C)n(c3C)c4ccc(F)cc4)C(=O)N2C1c5cccc(OC)c5OC)c6ccccc6 GNF Probe-like A F07 A A05
MMV007564 Cc1ccc(Cn2c(nc3ccccc23)N4CCC(CC4)C(=O)NCc5cccs5)cc1 GNF;GSK Drug-like B B10 B A06
MMV665917 Clc1ccc(NC(=O)N2CCN(CC2)c3ccc4nncn4n3)cc1 GNF Drug-like B A03 B A08
MMV000563 COc1ccc(cc1)C2Sc3ccccc3N=C4C2=C(O)c5ccccc45 GNF Drug-like B G08 B A09
MMV665891 c1ccc(cc1)c2ccc(cc2)c3nc4ccccc4[nH]3 GSK Drug-like B A08 B B10
MMV665909 Brc1ccccc1C(=O)Nc2nc(cs2)c3ccccn3 StJude Drug-like B E02 B B08
MMV000653 CCOc1ccccc1CNC(=O)C2C(N(CC(C)C)C(=O)c3ccccc23)c4cccs4 StJude Drug-like B B11 B B06
MMV020439 CCn1c(CN2CCN(Cc3ccccc3)CC2)nc4cc(NC(=O)c5cccs5)ccc14 GSK Drug-like A H08 A B06
MMV000570 CCc1ccc(Nc2cc(C)c3ccc(O)cc3n2)cc1 StJude Probe-like A F08 A B05
MMV666105 COCCN(C(C(=O)NCc1ccc(OC)cc1)c2ccc(cc2)C(C)C)C(=O)Cc3cccs3 GSK Drug-like B E06 B B04
MMV665977 CCOC(=O)C1=CN(CC)c2cc(N(C)CCc3ccc(OC)c(OC)c3)c(F)cc2C1=O GNF;GSK Probe-like A H02 A C03
MMV001246 CSc1ccccc1C(=O)Nc2nc(cs2)c3ccccn3 StJude Drug-like A F09 A C05
MMV665915 COc1ccc(cc1)c2nc(NC(=O)CS(=O)(=O)c3ccc(F)cc3)sc2C GNF;GSK Drug-like A A02 A C07
MMV665798 FC(F)(F)c1cccc(Nc2nc(nc3ncccc23)c4ccccc4)c1 GSK Drug-like B G03 B D09
MMV665935 FC(F)(F)c1ccc(Nc2nnnc3ccccc23)cc1 GNF;GSK Drug-like B C02 B D03
MMV666596 CSC1=NC(=Nc2c(C)cccc2C)C3(CCC(CC3)C(C)(C)C)N1c4ccc(Cl)cc4 GNF Probe-like A A07 A D03
MMV000642 COc1ccc(NC(=O)C2C(N(CC(C)C)C(=O)c3ccccc23)c4cccs4)cc1Cl GNF;StJude Probe-like A A09 A E03
MMV009060 CCN(CC)c1ccc(NC(=O)c2cccs2)cc1 GNF Drug-like B A09 B E04
MMV006309 CN(C)c1ccc(C=CC2=NC(=O)c3ccccc3O2)cc1 GNF;GSK;GNF Probe-like A A08 A E06
MMV019758 COc1ccc(cc1OC)C(=O)Nc2ccc3nc(cc(C)c3c2)N4CCCCC4 GSK Drug-like B D09 B E06
MMV000498 CCN(CC)c1cc(C)c2cc(NC(=O)c3cccc(OC)c3)ccc2n1 StJude Drug-like B F09 B E07
MMV011944 n1c(NCCO)c2c(cccc2)nc1Nc3cccc(OC)c3 GNF;GSK Drug-like B H11 B F08
MMV006937 Cc1ccc(cc1)c2cc3nc4CCCCc4c(O)n3n2 GNF Drug-like A C05 A F08
MMV019064 COc1cccc(c1)c2nn(C)c3sc(cc23)C(=O)NCCN4CCN(CC4)c5ccccc5F GSK Drug-like B G09 B F07
MMV007160 Cc1ccc(cc1)N2C3N(c4ccccc4C2N(c5ccccc35)S(=O)(=O)c6ccc(C)cc6)S(=O)(=O)c7ccc(C)cc7 GNF Probe-like A G07 A F05
MMV665827 CCOC(=O)C1=CN(CC)c2cc(N3CCCCC3)c(F)cc2C1=O GNF;GSK Probe-like A G03 A G10
MMV007907 Cc1ccc(Nc2nc(cs2)c3ccccn3)cc1 GNF Drug-like A F06 A H09
MMV000788 CC(C)OCc1cc(CN2CCN(CC2)c3cccc(Cl)c3)c(O)c4ncccc14 StJude Drug-like B E10 B H06
MMV142383 CC(C)(C)c1ccc(cc1)C(=O)Nc2nc3ccccc3s2 StJude Drug-like B B09 B H05
MMV006861 C1CN(CCO1)c2ccc(Nc3ccnc4cc5ccccc5cc34)cc2 GNF Probe-like A H06 A H05
MMV007839 C1(O)(CC(=O)c(ccc(OC)c2)c2O1)C(F)(F)C(F)(F)F GNF Drug-like A C10 A H02
MMV403679 c1(c(cnn1c2cccc(C)c2)C(=O)N3)N=C3n4nc(C)cc4NC(=O)c5cc(cccc6)c6o5 Commercial Drug-like C C08 C A04
MMV019670 O=C(Nc1ccc(cc1)N2CCN(Cc3ccccc3)CC2)c4cccs4 GSK Drug-like C B06 C A07
MMV396669 n1c(cc(C)nc1Nc(cc2)ccc2NC(CCc3ccccc3)=O)N4CCCC4 Commercial Drug-like C G09 C H03
MMV020654 CCC(O)c1ccc(Br)cc1NC(=O)c2cccc(Cl)c2 GSK Drug-like C H02 C D10
MMV306025 C1(=NC(N(C)C2=O)=O)C2=NC(=NN1CC)c3ccc(C(=O)OC)cc3 Commercial Drug-like C B08 C D03
MMV000963 n1c(NCc2ccccc2)c3c(cccc3)nc1Nc(cc4)ccc4OC GNF;StJude Drug-like C F11 C E04
MMV006319 Cc1cc(Nc2cccc(F)c2)nc(NCc3ccccc3)n1 GNF Drug-like C G11 C E05
MMV001318 Clc1cccc(NC(=O)Nc2ccc(Br)cc2)c1 StJude Drug-like C E05 C E08
MMV020660 COc1ccc(cc1OC)c2nonc2NC(=O)c3cccc(Cl)c3 GSK Drug-like C H03 C E10
MMV019266 Cc1sc2ncnc(Sc3nc4ccccc4[nH]3)c2c1C GSK Drug-like C G02 C F09
MMV073843 CN(C)c1ccc(cc1)N=Cc2ccc(cc2)N3CCOCC3 GNF Probe-like E A06 E A02
MMV000445 CCCCCCN1C(=N)N(CC(O)COc2cccc(C)c2)c3ccccc13 StJude Probe-like D D09 D A07
MMV006882 CCOC(=O)c1cnc2ccc(Cl)cc2c1NCCCN(C)C GNF Probe-like D G08 D A08
MMV020403 COc1ccc(cc1)c2cn3c(C(=O)Nc4ccccc4Cl)c(c5CCCCn2c35)c6ccccc6 GSK Probe-like E F05 E A08
MMV007127 OC1=C2C(Sc3ccccc3N=C2c4ccccc14)c5ccc(Br)cc5 GNF Probe-like D B08 D A09
MMV666123 CC(C)(C)c1ccc(cc1)C(=O)Nc2c3CSCc3nn2c4cccc(Cl)c4 StJude Probe-like D A03 D A10
MMV665886 CC(Oc1ccc(NC(=O)c2cccs2)cc1)C(=O)c3ccc(Cl)cc3 GSK Probe-like E H03 E A11
MMV084434 COc1ccc(C=C2SC(=NC2=O)Nc3ccc(F)cc3)c(OC)c1 GNF;GNF;GNF Probe-like E D07 E B07
MMV007577 Cc1ccccc1OCCSc2nc3ccc(NC(=O)c4ccccc4)cc3s2 GNF Probe-like D B11 D B06
MMV666109 CCOC(=O)C1(Cc2ccccc2)CCN(Cc3cccc(OC)c3O)CC1 StJude Probe-like D D05 D C02
MMV007020 CCOc1ccc2nc(C)cc(Nc3ccc(cc3)N(C)C)c2c1 GNF Probe-like E A09 E C02
MMV665936 Cc1ccc(cc1)S(=O)(=O)c2c(COC(=O)c3cccc(C)c3)c(nn2C)c4ccccc4 GNF Probe-like D E02 D C03
MMV006656 CCOC(=O)C1=CN(C)C=C(C1c2cc(Br)c(OCC)c(OC)c2)C(=O)OCC GNF Probe-like E H07 E C03
MMV006522 CCOc1ccc2nc(C)cc(Nc3ccc(Br)cc3)c2c1 GNF Probe-like E F11 E C05
MMV000720 Cc1ccnc(NC(c2cccc(OCc3ccccc3)c2)c4ccc5cccnc5c4O)c1 GSK;StJude Probe-like D E08 D C07
MMV000619 CCCCC(O)(C(CN1CCOCC1)c2ccc(Cl)cc2)c3ccc(Cl)cc3 StJude Probe-like D G10 D C08
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MMV000699 Cc1ccc(cc1)C2CC(n3nc(cc3N2)C(=O)N4CCN(CC4)C(c5ccccc5)c6ccccc6)C(F)(F)F StJude Probe-like D E07 D D09
MMV000326 Cc1ccc2nc(C)cc(Nc3cccc(c3)C(F)(F)F)c2c1 StJude Probe-like D C08 D D06
MMV007574 O=C(Nc1ccc(cc1)C23CC4CC(CC(C4)(C2)c5ccccc5)C3)c6cccs6 GNF Probe-like D A07 D D05
MMV665987 CCCCCCc1cc(O)c2C3=C(CCC(C)C3)C(=O)Oc2c1 GNF Probe-like D C04 D D04
MMV006825 n1c(Nc(cc2)ccc2OC)cc(C)nc1NCc3ccccc3 GNF Probe-like E H11 E E05
MMV008455 COc1ccc(cc1)C2C(C(=O)Nc3cccc(OC)c3)c4ccccc4C(=O)N2C5CCCCC5 GNF Probe-like D H09 D E08
MMV007199 COc1ccccc1N2C(=N)SC(=Cc3ccc(OCc4ccccc4F)cc3)C2=O GNF;GNF Probe-like D E09 D E09
MMV396717 c([nH]nc1c2c(O)cc(C)c(Cl)c2)(C3=O)c1C(c4ccccc4F)N3CCc(cc5)ccc5OC Commercial Probe-like E E10 E E10
MMV665898 COc1cc(cc(OC)c1OC)C(=O)Nc2ccc(cc2)c3nc4ccccc4[nH]3 GSK Probe-like E B03 E F09
MMV000621 CCCCCCC(O)(C(CN1CCOCC1)c2ccccc2)c3ccc(F)cc3 StJude Probe-like D H10 D F08
MMV019741 Cc1ccc(C)c(Cn2c(nc3ccccc23)N4CCC(CC4)C(=O)NCc5cccs5)c1 GSK Probe-like D C10 D F06
MMV007654 Cc1ccc(C)c(c1)c2csc(Nc3ccc(C)c(C)c3)n2 GNF Probe-like E A05 E F05
MMV666095 CCCc1c(C)nc2ccc(Br)cc2c1O GNF Probe-like D G05 D F03
MMV396594 c12c(nc(c3ccc(OC)cc3)nc1N4CCN(C(=O)C5CCCCC5)CC4)sc(CCCC6)c26 Commercial Probe-like E F08 E F02
MMV666106 O=C(NC1CCCCC1)C(N(CCc2ccccc2)C(=O)c3occc3)c4cccs4 GSK Probe-like D H05 D G03
MMV396663 c1(C(c(cccn2)c2)N3CCC(CC3)Cc4ccccc4)c(C)c(C)sc1NC(=O)c5ccco5 Commercial Probe-like E B08 E G03
MMV007396 Cc1ccccc1OCCSc2nc3ccc(NC(=O)c4cccs4)cc3s2 GNF Probe-like D C11 D G06
MMV000617 COc1ccc(cc1)C(O)(CCC(C)C)C(CN2CCOCC2)c3ccc(Cl)cc3 StJude Probe-like D F10 D G07
MMV011522 Cc1ccc(Nc2nc(N)c3ccccc3n2)cc1Cl GNF;StJude Probe-like E G10 E G11
MMV007113 c1ccc(cc1)C2=Nc3ccccc3N=C(c4ccccc4)c5ccccc25 GNF Probe-like D G07 D H09
MMV667489 N1C(c2cccc(cccc3)c23)C(CC=C4)C4c5c1c(Cl)ccc5C(OC)=O Commercial Probe-like E B10 E H03
MMV006169 C(Nc1nc(Nc2ccccc2)nc3ccccc13)c4ccccc4 GNF Probe-like E E09 E B05  
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Chapter 2 – Table 2: Subset of MMV Malaria box molecules of interest 
 
Five compounds chosen from the MMV Malaria box based on potency and similar 
efficacies against C. parvum. 
 
Name Structure IC50	(μM)	vs	T.	gondii	(95%	CI)
MMV000720 0.44	(0.30-0.66)
MMV403679 0.13	(0.11-0.14)
MMV001246 0.55	(0.44-0.70)
MMV000642 6.31	(4.25-9.36)
MMV006169 1.15	(0.74-1.79)
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Chapter 2 – Table 3: MMV006169 structural analogs 
 
Seventy-four structural analogs of MMV006169 were ordered or synthesized (by Drs. 
Fanny Tran and Nicholas Westwood at the University of St. Andrews), all containing a 
conserved 2,4-diaminoquinazoline chemical scaffold. Calculated IC50 values for each 
analog and corresponding 95% confidence intervals are reported. Excessively wide 
confidence intervals are reported as “n/a”.  
 
Structure T. gondii IC50 (µM) (95% CI)
C. parvum IC50 
(µM) (95% CI)
MMV006169 1.15 (0.74-1.79) 1.5 (1.16-1.94)
FT14.116.2 0.26 (0.17-0.39) 2.83 (2.36-3.40)
EN01.068.2.3 0.44 (0.34-0.58) 4.09 (2.34-7.15)
EN01.042 0.46 (0.35-0.60) 0.87 (0.62-1.23)
OSSL_723641 0.55 (0.38-0.80) 0.44 (0.38-0.52)
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EN01.068.2.5 0.58 (0.31-1.09) 1.08 (0.64-1.80)
OSSL_324342 0.58 (0.46-0.75) 6.19 (2.80-13.69)
PA-Br 0.59 (0.16-2.19) 2.65 (2.30-3.05)
HG014 0.70 (0.25-1.94) 3.45 (3.10-3.84)
PA-01-22 0.74 (0.37-1.49) >10 (n/a)
FT14.025.2 0.78 (0.52-1.17) 6.58 (4.63-9.36)
FT14.079.2 0.82 (0.34-1.99) >10 (n/a)
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EN01.031 0.88 (0.32-2.41) 0.64 (0.48-0.87)
OSSL_324319 0.93 (0.71-1.20) 8.89 (6.35-12.45)
FT07.032.2 0.96 (0.80-1.16) >10 (n/a)
CP01009 1.05 (0.58-1.91) 6.62 (6.08-7.22)
PA-01-09 1.06 (0.22-5.01) 5.82 (5.05-6.70)
FT07.031.7 1.01 (0.78-1.31) >10 (n/a)
HG021 1.03 (0.78-1.36) >10 (n/a)
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FT14.006.2 1.11 (0.74-1.68) 1.33 (1.00-1.76)
FT14.007.2 1.124 (0.70-1.80) 9.93 (n/a)
OSSL_723668 1.13 (0.57-2.25) 1.74 (1.29-2.39)
OSSL_723788 1.19 (0.89-1.60) 3.92 (1.25-12.32)
OSSL_102463 1.21 (0.81-1.80) 9.50 (n/a)
FT07.031.1 1.26 (1.08-1.47) >10 (n/a)
EN01.065 1.27 (0.94-1.71) 0.37 (0.26-0.53)
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PA-01-20 1.33 (0.72-2.47) 5.35 (4.86-5.88)
OSSL_102470 1.34 (1.07-1.67) 0.93 (0.64-1.40)
OSSL_324373 1.42 (1.04-1.92) 4.73 (3.37-6.62)
OSSL_325124 1.43 (0.96-2.12) 5.50 (4.02-7.53)
OSSL_102466 1.45 (1.07-1.96) 5.60 (2.97-10.58)
FT07.031.6 1.45 (1.01-2.08) 1.03 (0.83-1.29)
FT14.084.1 1.59 (0.94-2.68) 4.63 (3.88-5.53)
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OSSL_723748 1.60 (0.90-2.84) 4.54 (3.23-6.36)
HG009 1.62 (1.13-2.32) 4.35 (3.92-4.83)
OSSL_102469 1.66 (1.29-2.14) 4.12 (1.62-10.47)
FT07.033.2 1.72 (1.55-1.91) 1.03 (0.18-6.08)
AP005 1.79 (0.68-4.71) 1.01 (0.77-1.32)
EN01.098 1.81 (1.34-2.45) 0.98 (0.85-1.14)
OSSL_102476 1.87 (1.55-2.26) 2.69 (1.66-4.37)
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EN01.096 1.97 (1.65-2.35) 1.37 (1.15-1.63)
CP01007 1.98 (1.40-2.80) 6.44 (6.06-6.84)
HG019 2.00 (1.48-2.72) 1.41 (1.13-1.75)
FT14.078.4 2.09 (1.78-2.44) >10 (n/a)
OSSL_723692 2.12 (1.83-2.46) 0.93 (0.77-1.12)
AP002 2.24 (1.26-3.97) 0.46 (0.35-0.61)
HG015 2.31 (1.85-2.89) 2.74 (2.31-3.25)
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EN01.115 2.48 (1.68-3.67) 2.41  (2.13-2.72)
OSSL_324325 2.50 (1.63-3.86) 3.40 (1.97-5.85)
OSSL_324381 2.51 (2.07-3.04) >10 (n/a)
EN01.134 2.55 (2.13-3.05) 1.45 (1.20-1.77)
AP003 2.56 (0.93-7.05) 0.69 (0.54-0.89)
PA-01-26 2.81 (n/a) 3.85 (3.31-4.47)
OSSL_324383 3.09 (2.49-3.83) 3.92 (2.64-5.80)
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EN01.131 3.10 (2.45-3.91) 0.34 (0.27-0.43)
OSSL_723780 3.22 (2.50-4.15) 1.15 (0.94-1.40)
OSSL_324318 3.30 (2.42-4.50) 4.24 (3.41-5.27)
OSSL_102478 3.33 (2.56-4.33) 1.25 (0.91-1.62)
OSSL_324399 3.36 (2.40-4.72) 1.99 (1.51-2.63)
OSSL_324316 3.69 (3.17-4.29) >10 (n/a)
CP01004 3.94 (n/a) 4.48 (3.95-5.08)
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EN01.132 4.69 (4.03-5.46) 0.78 (0.67-0.91)
FT14.095.2 5.69 (3.89-8.33) 0.82 (0.65-1.03)
EN01.095 5.71 (3.95-8.25) 1.68 (1.51-1.87)
PA-01-21 5.96 (n/a) 4.31 (3.66-5.07)
FT14.026.2 6.57 (n/a) 2.33 (1.90-2.87)
OSSL_723607 7.28 (n/a) >10 (n/a)
PA-01-11 11.54 (n/a) 8.12 (5.32-12.40)
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PA-01-12 >18.18 (n/a) 3.76 (3.16-4.47)
PA-01-27 >18.18 (n/a) 9.46 (8.68-10.30)
FT14.027.2 >18.18 (n/a) >10 (n/a)
OSSL_324334 >18.18 (n/a) >10 (n/a)
OSSL_324392 >18.18 (n/a) >10 (n/a)
FT14.092.2 >18.18 (n/a) 0.69 (0.58-0.83)
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Chapter 2 – Table 4: SAR for phenotypic separation 
 
Eleven structural analogs of MMV006169 were chosen based on similarities and 
differences in potency between T. gondii and C. parvum and/or inclusion of major 
modifications to the MMV006169 backbone. Analogs are listed from most to least potent 
against T. gondii. INH=inhibitor, NE=no effect, PAR INH=partial inhibition. 
 
 
 
 
T.	gondii C.	parvum
- MMV006169 H H H 1.15 1.5 INH INH
C-1 OSSL_324342 	3-CF3 H H 0.58 6.19 INH INH
C-2 FT14.079.2 NHCH3 H CH2Ph 0.82 >10 INH
C-3 EN01.031 H H 3-OMe 0.88 0.64 INH
C-4 FT07.032.2 	3-CF3 H 4-OMe 0.96 >10 INH
C-5 FT07.031.7 2-OMe,	3-CF3 H H 1.01 >10 INH NE
C-6 FT07.031.1 2-OMe,	3-CF3 H 4-OMe 1.26 >10 PAR	INH NE
C-7 EN01.065 H H 2-OMe 1.27 0.37 INH INH
C-8 FT14.084.1 Cyclohexane H NHCH(CH3)2 1.59 4.63 INH
C-9 AP005 4-OMe H H 1.79 1.01 INH
C-10 FT14.078.4 Ph H NHCH3 2.09 >10 PAR	INH
C-11 FT14.027.2 	3-CF3 8-OMe 4-OMe >18.18 >10 NE NE
IC50	(μM) InvasionReplicationAnalog	
Number
Compound R1 R2 R3
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Chapter 2 – Table 5: Primers for cloning T. gondii CDC48Ap and CDC48Cy 
 
All primers were synthesized by Sigma Aldrich (The Woodlands, TX) with no special 
modifications. Sequences homologous to pGADT7 are underlined and were used for 
cloning in yeast. 
 
 
Primer Name Sequence (5'è3'); Sequence homolgous to pGADT7 is underlined 
1 CDC48ApFw GAGTACCCATACGACGTACCAGATTACGCTATGGGGACTGCGTGGTGCCC
2 CDC48ApRev ACAAGCCGACAACCTTGATTGGAGACTTGATCACTTTGTTTCCTTCGCCG
3 CDC48Ap480Fw CGATCTATCGCACCCCAC
4 CDC48Ap978Fw ATCAAAGTCACCCCACAG
5 CDC48Ap1489Fw GCGTATTGCTTCACGGTT
6 CDC48Ap2007Fw CAGCTCTGTCTGGAAGCC
7 CDC48Ap2504Fw AATGGACTCGATCGCGAA
8 CDC48CyFw GAGTACCCATACGACGTACCAGATTACGCTATGGCCGGCGGCATTCGCAG
9 CDC48CyRev ACAAGCCGACAACCTTGATTGGAGACTTGACTACGAGTAGAGGTCATCGT
10 CDC48Cy498Fwd CGTCCTGTAGAATTCAAG
11 CDC48Cy1018Fwd TCCTTACCCTCATGGACG
12 CDC48Cy1518Fwd TACCCTATCGACCATCCT
13 CDC48Cy2002Fwd TTCTCCAGGCAACGTTGA  
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Chapter 2 – Figure 1: Effect of MMV006169 on T. gondii growth kinetics 
A) YFP-based growth assay using varying concentrations of MMV006169. Values are 
represented as percent positivity over time. The highest fluorescence reading obtained 
during screening is assigned 100%, while blank wells containing cells and media are set 
to 0%. All other values are assigned between those points.  B) IC50 curve extrapolated 
from YFP-based growth assay data. The concentration of MMV006169 necessary to 
inhibit 50% of parasites is 1.15 µM (95% confidence interval: 0.74-1.79). Error bars 
represent standard deviation (n=3). C) Structure of MMV006169 with 2,4-
diaminoquinazoline scaffold highlighted in red. 
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Chapter 2 – Figure 2: MMV006169 is not toxic to HFFs 
Viability of host cells was determined via ATPase assay. HFFs were exposed to 
MMV006169 for 24-hours before host cell lysis and quantification of ATP levels by 
luminescence. Luminescence is reported as relative luminescence units (RLU). All wells 
were normalized to a control of HFFs and media with no CellTiter-Glo reagent. Sodium 
azide was included to represent a “kill control” in which we know the cells are no longer 
generating ATP.  Bars represent mean +/- standard deviation, n=3. Data were analyzed 
using a one-way ANOVA (***p≤0.001).  
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Chapter 2 – Figure 3: MMV006169 inhibits T. gondii invasion and replication, not 
motility.  
Effect of MMV006169 on T. gondii invasion, motility, and replication. A) MMV006169 
inhibits T. gondii invasion at 10 µM. Two color invasion assays were scored blindly by 
immunofluorescence. (n=3, *p≤0.05 as determined by one-way ANOVA). B) 
MMV006169 does not inhibit T. gondii motility.  Parasite trails were stained with α-
SAG1 antibody and quantified by immunofluorescence (n=3, results analyzed by one-
way ANOVA). C) MMV006169 inhibits T. gondii replication at 5 µM. HFFs were 
infected with 2F1 YFP2 strain T. gondii and grown in the presence (red) or absence (blue) 
of compound for 36 hours. The average number of parasites per vacuole in vacuoles 
containing two or more parasites was determined by immunofluorescence (n=3, *p≤0.05, 
**p ≤ 0.01, ***p ≤ 0.001, **** p ≤ 0.0001 as determined by two-way ANOVA).  
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Chapter 2 – Figure 4: MMV006169 analogs are not toxic to host cells after 24 
hours 
Viability of host cells was determined via ATPase assay. HFFs were exposed to 10 µM of 
each analog for 24-hours before host cell lysis and quantification of ATP levels by 
luminescence. Luminescence is reported as relative luminescence units (RLU). All wells 
were normalized to a control with no CellTiter-Glo reagent. Sodium azide was included 
to represent a “kill control” in which we know the cells are no longer generating ATP.  
Bars represent mean +/- standard deviation, n=3. Data were analyzed using a one-way 
ANOVA (****p≤0.0001).  
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Chapter 2 – Figure 5: Effect of MMV006169 structural analogs on replication 
Quantification of T. gondii replication after 36 hours. Eleven compounds from the SAR 
screen were assayed at 5 µM. The number of parasites per vacuole (in vacuoles 
containing two or more parasites) was determined at each time point and compared to 
DMSO-treated controls. (n=3; , *p≤0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001  as 
determined by two-way ANOVA). 
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Chapter 2 – Figure 6: Effect of MMV006169 structural analogs on T. gondii 
invasion 
Quantification of the ability of T. gondii tachyzoites to invade HFFs. Five compounds 
from the SAR screen were assayed at 10 µM and scored blindly by immunofluorescence. 
(n=3; ****p ≤ 0.0001 as determined by one-way ANOVA). 
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Chapter 2 – Figure 7: MMV006169 structural analogs cannot initiate replication 
Quantification of the number of two-parasite containing vacuoles for analogs with the 
most severe invasion defects. Replication assays were differentially stained for 
intracellular and extracellular parasites at 36 hours using a standard two-color invasion 
assay protocol. (n=3, 100 fields per coverslip). 
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Chapter 2 – Figure 8: Targeted yeast three-hybrid and structure of Mtx-
MMV006169 
A) Schematic of targeted yeast three-hybrid ternary complex containing the DNA-
binding (DBD) and activation domains (AD) of the GAL4 transcription factor (green) 
and the CID. The CID is comprised of methotrexate (blue) fused to MMV006169 (red) 
by a flexible linker (purple). The methotrexate moiety of the CID interacts with DHFR 
and if MMV006169 interacts with either isoform of CDC48, reporter activation will 
occur. B) Structure of MMV006169-based CID. Methotrexate is outlined in blue, 
MMV0006169 in red, and the linker is found between the two.  
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Chapter 2 – Figure 9: CID Competition Assay with Mtx-MMV006169 
pGADCDPK1-containing yeast can activate reporter genes and grow in histidine lacking 
media upon the addition of 25 µM CID7 (blue bars). The addition of 25 µM Mtx-
MMV006169 to this functioning positive control (red bars) inhibited reporter activation. 
This implies that Mtx-MMV006169 can enter yeast and compete for binding with CID7.  
Bars represent mean +/- standard deviation; n=2. Data were analyzed using paired t-tests 
(**p≤0.01, ****p≤0.0001). 
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Chapter 2 – Figure 10: Targeted yeast three-hybrid liquid growth assay suggests 
MMV006169 does not interact with CDC48Ap. 
Growth of yeast in media lacking histidine is a reflection of reporter activation. The 
positive control, CDPK1, is able to grow more robustly in the presence of CID7 than in 
DMSO (red versus blue bars), implying a direct interaction between the CID and 
CDPK1. CDC48Ap grows to the same level in the presence of Mtx-MMV006169 
(purple) and DMSO (green), meaning the histidine reporter gene has not been activated. 
Bars represent mean +/- standard deviation; n=3. Data were analyzed using paired t-tests 
(*p≤0.05, **p≤0.01). 
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Chapter 2 – Figure 11: Targeted yeast three-hybrid liquid growth assay suggests 
MMV006169 does not interact with CDC48Cy. 
Growth of yeast in media lacking histidine is a reflection of reporter activation. The 
positive control, pGADCDPK1, is able to grow more robustly in the presence of CID7 
than in DMSO (red versus blue bars), implying a direct interaction between the CID and 
CDPK1. pGADCDC48Cy grows to a similar level in the presence of Mtx-MMV006169 
and DMSO (green and purple bars), meaning the histidine reporter gene has not been 
activated. Bars represent mean +/- standard deviation; n=3. Data were analyzed using 
paired t-tests (*p≤0.05, **p≤0.01). 
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CHAPTER 3: APPROACHES TO IDENTIFYING THE TARGET(S) OF 
MMV006169 
 
3.1 Introduction 
Studies aimed at identifying the target of small molecules face a variety of 
challenges. 1) Is the putative target identified the biologically relevant target? 2) Does the 
molecule have multiple targets? 3) Is the compound working through the organism of 
interest or through environmental/host cell mechanisms? To ensure these questions are 
answered adequately, multiple strategies for target identification are commonly used in 
parallel. Recent advances in high-throughput screening (Farrell et al. 2012), CID 
development (Tran et al. 2013), and the CRISPR/Cas9 system for gene deletions (Shen et 
al. 2014, Sidik et al. 2014, Sidik et al. 2016) have assuaged the process of target 
confirmation.  
Full genome mutagenesis-based approaches for initial target identification have 
been successful in the study of T. gondii using several mutagens (Pfefferkorn and 
Pfefferkorn 1979, Morrissette et al. 2004, Gubbels et al. 2008, Coleman and Gubbels 
2012, Farrell et al. 2014) and have led to the isolation of mutants resistant to varying 
levels of compound. However, if the target of these molecules is essential, the resistant 
mutants often have mutations in drug transporters, which render the parasite resistant 
without providing direct target information. This approach is also less informative if the 
compound has more than one target, as one may not be able to distinguish between partial 
compound resistance in phenotypic assays.  
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We have recently shown that a yeast three-hybrid approach to target 
identification can be useful for probing the T. gondii genome (Odell et al. 2015). Yeast 
three-hybrid has the advantage of examining protein-small molecule interactions without 
directly inhibiting the parasite life cycle. The interaction is first identified in yeast, and 
can then be brought back into the parasite for target confirmation. This approach is 
beneficial in that it allows one to look at essential genes and to identify more than one 
target at a time.  
  Here, we present approaches towards the identification of target(s) of the 
Medicines for Malaria Venture compound MMV006169. We have previously shown that 
MMV006169 inhibits the growth of both T. gondii and C. parvum (Bessoff et al. 2014), 
and specifically reduces T. gondii invasion and replication, with no effect on motility 
(Chapter 2). We examined the possibility of MMV006169 interacting with TgCDC48Cy 
or TgCDC48Ap based on structural similarities between MMV006169 and a known p97 
inhibitor (Chapter 2) (Chou et al. 2011). Targeted yeast three-hybrid experiments to 
determine if MMV006169 could interact with TgCDC48Cy or TgCDC48Ap came up 
negative, suggesting the compound is working through an interaction with a different 
parasite and/or host cell protein target. The work in this chapter describes whole genome 
mutagenesis attempts to generate parasites resistant to MMV006169 and its analogs. 
Yeast three-hybrid library screens are performed identifying a putative host cell protein 
target for MMV006169, whose T. gondii isoforms show no interaction with 
MMV006169 by targeted yeast three-hybrid. 
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3.2 Materials and Methods 
3.2.1 Parasite culture 
T. gondii RH ΔhxgprtΔku80 and 2F1 YFP2 tachyzoites (Gubbels et al. 2003), 
kindly provided by Dr. Marc-Jan Gubbels, were passaged serially in confluent 
monolayers of human foreskin fibroblasts (HFFs) maintained at 37°C (5% CO2 and 
constant humidity) in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented 
with 10mM HEPES, pH 7.2, 10 units/mL penicillin G sodium salt, 10 units/mL 
streptomycin sulfate, and containing 1% heat-inactivated fetal bovine serum as 
previously described (Roos et al. 1994).   
 
3.2.2 N-ethyl-N-nitrosourea titration and plaque assay 
 Titration of N-ethyl-N-nitrosourea (ENU) was performed as previously 
described with the following modifications (Coleman and Gubbels 2012, Farrell et al. 
2014). Upon fresh lysis, 1 mL of 2F1 YFP2 tachyzoite were plated on a confluent T25 
tissue culture flask of HFFs and incubated at 37°C for 24 hours in Ed1 medium. Medium 
was replaced with 10 mL of Ed1 diluted (1:10) in DMEM and incubated at 37°C for 10 
minutes. ENU was added in 0, 14.6, 29.3, 58.6, or 117 µL volumes (0.85M stock in 
DMSO) per flask (working dilutions of ENU will be 1.25, 2.5, 5, and 10 mM, 
respectively) and DMSO such that total is 117 µL for each flask. Flasks were incubated 
for 4 hours in at 37 °C and then washed with cold sterile PBS before harvesting by 
syringe release, passage through a 3-µm Nuclepore filter (Whatman, Piscataway, NJ), and 
gently pelleting for 4 minutes at 1,100 x g. 10,000 parasites in 3 mL of Ed1 media were 
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added to one well in a 6-well plate. Parasites were serially diluted 10-fold across the 
remaining wells. Plates were incubated at 37°C for 7 days to allow plaques to form. After 
incubation, medium was aspirated and cell monolayers were fixed with 100% ethanol. 
Monolayers were stained using crystal violet solution containing 2% w/v crystal violet 
and 0.8% w/v oxaloacetate in ethanol, washed with PBS, and then air dried at room 
temperature.  
 
3.2.3 ENU mutagenesis 
Mutagenesis was performed as previously described with a few modifications 
(Coleman and Gubbels 2012, Farrell et al. 2014). One milliliter of freshly lysed 2F1 
YFP2 parasites (in Ed1 media) were seeded onto a confluent monolayer of HFFs in a T25 
tissue culture flask and incubated at 37°C for 24 hours. Medium was replaced with 10 
mL of Ed1 diluted 1:10 in DMEM and placed at 37°C for 10 minutes. Flasks were treated 
with 72.7 µL ENU (100 mg/mL stock in DMSO) for 4 hours at 37°C. Each flask was 
washed three times with cold filter sterilized PBS. Monolayers were harvested by syringe 
release, passed through a 3-µm Nuclepore filter (Whatman, Piscataway, NJ) to eliminate 
host cell debris, and gently pelleted (1,100 x g) for 4 minutes. The entire pellet was added 
to a single T25 tissue culture flask and allowed to lyse naturally. Mutagenized parasites 
were then passaged in media containing the EC90 of each compound of interest. 
 
3.2.4 Compound-induced cyst staining 
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HFFs were grown to confluence on 12 mm circular coverslips in 12-well plates. 
MMV006169 resistant parasites were harvested by syringe release, passed through a 3-
µm Nuclepore filter (Whatman, Piscataway, NJ) to eliminate host cell debris, and gently 
pelleted (1,100 x g, 4 minutes). Parasites were added to each coverslip at a multiplicity of 
infection of 4x105 in the presence of 3 µM MMV006169. After 7 days, coverslips were 
incubated in fixative solution (1X PBS + 4% v/v paraformaldehyde) for 20 minutes, 
permeabilized (1X PBS + 0.25% v/v Triton X-100) for 15 minutes, and blocked for 30 
minutes in 1X PBS + 1% w/v bovine serum albumin. Coverslips were incubated for 30 
minutes in rabbit polyclonal anti-Toxoplasma (1:2000, catalog #90700556; AbD Serotec, 
Raleigh, NC) and then with goat anti-rabbit IgG conjugated to Alexa 488 (Invitrogen, 
2mg/mL) at a 1:500 dilution together with TRITC-conjugated Dolichos biflorus lectin 
(Sigma-Aldrich, St. Louis MO) at a dilution of 1:100 for 60 min. 2F1 YFP2 parasites 
treated with DMSO for 24 hours were included as a control. Coverslips were sealed to the 
surface of glass slides using nail polish and visualized at 100X on a Nikon Eclipse TE300 
epifluorescence microscope.   
 
3.2.5 YFP-based growth assay 
Growth of T. gondii strain 2F1 YFP2 parasites was monitored as described 
previously (Gubbels et al. 2003) with several modifications. Both parasites and HFFs 
were continuously cultured in HyClone DMEM/high modified medium without phenol 
red (Thermo Fisher Scientific) containing 1 or 10% v/v heat-inactivated fetal bovine 
serum (FBS). Medium was supplemented with 10 units/mL penicillin G sodium salt, 10 
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units/mL streptomycin sulfate, 10 mM HEPES, pH 7.2. Special Optics black/clear 384-
well tissue culture-treated plate (BD Falcon) were seeded with 5x103 HFFs (in 50 µL 
medium containing 10% v/v FBS) and grown at 37°C (5% CO2 with constant humidity). 
Upon confluence, wells were washed with culture medium containing 1% v/v FBS. 
Thirty microliters of culture medium containing 1% v/v FBS was added to each well. 2F1 
YFP2 tachyzoites were syringe released, passed through a 3-µm Nuclepore filter 
(Whatman, Piscataway, NJ), and gently pelleted (1,100 x g) for 4 minutes. Parasites were 
resuspended in culture medium supplemented with 1% v/v FBS and diluted to 1x105 
parasites/mL. Twenty microliters of medium containing 2,000 parasites was added to 
each test well. Serially diluted test compounds were added to each well in a 5 µL volume. 
Plates were incubated at 37°C in 5% CO2 (constant humidity) and fluorescence was read 
daily for 8 days from the bottom of the plate with the lid in place using a Synergy 2 
microplate reader (BioTek, Winooski, VT; excitation 485/20 and emission 528/20). 
Pyrimethamine was included as a positive control in each plate. The IC50 of each 
compound was determined as described previously (Bessoff et al. 2014). 
 
3.2.6 cDNA library preparation and negative selection 
A previously generated T. gondii oligo-dT primed cDNA library containing 
2.4x106 total CFU with an average insert size of 1.65 kb in the vector pGADT7 
(generously provided by Dr. Michael White, University of South Florida) and the vector 
pGBKeDHFR was used to transform competent BAPJ69-4A yeast cells as described 
(Kvaal et al. 2002, Baker et al. 2003, Clontech 2007, Shaffer et al. 2012). The resulting 
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transformed yeast culture was plated on 50 x 150 mm diameter yeast drop out media 
plates containing 2% w/v glucose and lacking leucine and tryptophan (SC +Glu –trp –
leu) and incubated at 30°C for 5 days. Plates were then placed at 4°C overnight to harden 
the media. Transformants were pooled by flooding each plate with 3 mL 1xTE buffer and 
scraped with a rubber policeman. All yeast was pooled, resuspended in glycerol solution, 
and frozen in aliquots containing 4.35x107 CFU/mL.  
Negative selection was performed on a freshly thawed aliquot of pre-
transformed yeast (containing library and pGBKeDHFR) by plating it on 20 x 150 mm 
plates of drop out media (SC +Glu –trp –leu) containing 0.5 g/L 5-fluoroorotic acid (5-
FOA, Zymo Research) similar to that previously described (Chidley et al. 2011). The 
surviving yeast transformants were pooled and aliquoted at 2x107 CFU/mL. A single 
aliquot of yeast is thawed for each library screen.  
 
3.2.7 Titering 3-Amino-1, 2, 4-triazole (3-AT) for library screens 
A 5M solution of 3-AT (MP Biomedicals) was two-fold serially diluted and 
plated (SC +Glu –trp –leu) such that final concentrations of 5 mM, 2.5 mM, 1.25 mM, 
0.63 mM, and 0.31 mM were obtained. The positive control CID7 (or DMSO) was spread 
onto each plate at a final concentration of 5 µM. Plates were allowed to incubate at room 
temperature overnight in the dark. Library containing yeast was then plated at 7x107 
CFU/mL and incubated at 30°C for 7 days. Colonies on each plate were marked and 
recorded daily until a lawn was seen on plates containing CID7 with no 3-AT. The 
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concentration of 3-AT in which no growth was seen on DMSO control plates, but was 
seen upon CID treatment was used in all future experiments. 
 
3.2.8 Yeast three-hybrid library screens 
On the day prior to each library screen, CID was spread onto yeast drop out 
media containing 2% w/v glucose selective for the cDNA library (leucine), DNA-binding 
domain (pGBKeDHFR, tryptophan), and the histidine reporter gene (SC +Glu –trp –leu –
his) at a chosen concentration (25 mM for Mtx-MMV006169). 3-AT was also spread on 
each plate at a final concentration of 1.25 mM. These plates were left at room 
temperature overnight to allow the CID and compound to absorb into the yeast media.  A 
negative control plate was set up in parallel containing DMSO in place of CID. A library 
aliquot was removed from -80°C, diluted, counted, and plated at 5x107 CFU/mL (20x 
library coverage).  Plates were incubated at 30°C and monitored daily until growth was 
seen on negative control (DMSO + 3-AT) plates.  
 
3.2.9 Yeast three-hybrid reporter confirmation 
Confirmation of reporter gene activation was done similarly to that previously 
published with several modifications (Odell et al. 2015). A single colony of yeast isolated 
from a yeast three-hybrid library screen was used to inoculate 3 mL of synthetic complete 
media supplemented with glucose lacking tryptophan and leucine (SC +Glu –trp –leu) 
and incubated with shaking for 48 hours. On the day of the assay, 200 µL of yeast was 
sub-cultured into 4 mL of SC +Glu –trp –leu and incubated for 4 hours until the yeast 
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reached log phase. The yeast was counted and diluted to 2x105 cells/mL and 25 µL was 
used to inoculate the wells of a 96-well plate (BD Falcon) containing 125 µL SC +Glu –
trp –leu –his. Wells were also treated with 1.5 µL of 2.5 mM CID (or DMSO) and 1.5 µL 
of 50 mM 3-AT to reduce background growth. Media alone (150 µL) with 1.5 µL DMSO 
and 1.5 µL 3-AT were included as negative control. A positive control including 125 µL 
media, 1.5 µL 2.5 mM CID7, 1.5 µL 50 mM 3-AT, and 25 µL (2x105) yeast expressing 
pGBKeDHFR and pGADBRADIN were included in each assay plate. Plates were 
parafilmed and incubated with shaking (200 rpm). The OD600 for each well was recorded 
daily from the bottom of the plate with the lid in place using a Synergy 2 microplate 
reader (BioTek, Winooski, VT). The assay was terminated with robust growth was 
observed in positive control wells.  
 
3.2.10 Construction of pGADNDH2-1 and pGADNDH2-2 
 Plasmid construction was completed using restriction enzymes and Phusion high 
fidelity polymerase purchased from New England BioLabs (Ipswitch, MA). All primers 
were synthesized by Sigma Aldrich (The Woodlands, TX). To construct pGADNDH2-1, 
pGADT7 (Clontech Laboratories, Mountain View, CA), was digested with SacI and 
NdeI. TgNDH2-1 was amplified from RH ΔhxgprtΔku80 cDNA using primers 14 and 15 
(Chapter 3 – Table 3). Gel extracted digested plasmid and the TgNDH2-1 PCR product 
were co-transformed into competent AH109 yeast as previously described (Gietz and 
Schiestl 2007). Transformants were selected on yeast drop out plates (SC +Glu –leu) and 
incubated at 30°C for 48 hours. The resulting plasmid was screened by restriction digest 
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and sequenced using primers 16 and 17 (Chapter 3 – Table 3).  pGADNDH2-2 was 
cloned as described above using primers 18-22. 
 
3.2.11 Targeted yeast three-hybrid liquid assay 
 To perform targeted yeast three-hybrid assays a plasmid containing the 
hypothesized MMV006169 target (pGADNDH2-1 or pGADNDH2-2) and a plasmid 
encoding E. coli dihydrofolate reductase fused to the Gal4 DNA-binding domain 
(pGBKeDHFR) was co-transformed into competent BAPJ69-4A yeast cells (a generous 
gift from Dr. Donald Doyle, Georgia Institute of Technology), plated on yeast drop out 
plates (SC +Glu –trp –leu) and grown at 30°C. A single colony of the resulting co-
transformants was grown overnight in 3 mL of synthetic complete liquid media (SC +Glu 
–trp –leu). After 24 hours, 200 µL of the yeast culture was used to inoculate 4 mL of SC 
+Glu –trp –leu and incubated for 4 hours with shaking (200 rpm). Log phase cells 
(determined by OD600) were counted and diluted to 2x105 cells/mL. 25 µL was used to 
inoculate each test well in a 96-well plate (BD Falcon) containing 125 µL SC +Glu –trp –
leu –his. CID (1.5 µL of 2.5 mM or DMSO) and 3-AT (1.5 µL of 50 mM) were added to 
test wells. As a negative control, 1.5 µL DMSO and 1.5 µL 3-AT were added to well 
containing 150 µL of media alone. BAPJ69-4A strain yeast expressing pGBKeDHFR and 
a plasmid encoding the Gal4 activation domain fused to TgBRADIN (Odell et al. 2015) 
were used as a positive control (125 µL media, 1.5 µL 2.5 mM CID7, 1.5 µL 50 mM 3-
AT, and 25 µL yeast). Plates were sealed with parafilm and incubated with shaking (200 
rpm) at 30°C. With the lid in place, the OD600 for each well was recorded from the 
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bottom of the plate using a Synergy 2 microplate reader (BioTek, Winooski, VT). Plates 
were read daily and the assay was terminated when robust growth was observed in 
positive control wells.  
 
3.3 Results 
3.3.1 Isolation of MMV006169 resistant mutants 
In an attempt to identify the target(s) of MMV006169, we implemented a whole 
genome mutagenesis approach that has previously proven successful in the study of T. 
gondii (Pfefferkorn and Pfefferkorn 1979, Morrissette et al. 2004, Gubbels et al. 2008, 
Coleman and Gubbels 2012, Farrell et al. 2014). We used N-ethyl-N-nitrosourea (ENU), 
a DNA alkylating agent, which works primarily by nucleotide substitution with a 
preference for A-T to T-A transversions or A-T to G-C transitions (Acevedo-Arozena et 
al. 2008, Farrell et al. 2014). This approach allows us to interrogate the entire genome, 
including essential genes, which is not possible using other deletion or gene interruption-
based techniques. It was previously shown that by inducing 70% killing of parasites, one 
could generate a parasite line with 10-100 mutations per genome (Pfefferkorn and 
Pfefferkorn 1979, Farrell et al. 2014). Since ENU is unstable in liquid stocks, we began 
by titering and pre-aliquoting our mutagen to avoid further freeze thaw cycles. By 
exposing parasites to varying concentrations of mutagen and performing plaque assays on 
each population, we determined that treating parasites at a final concentration of 6.31 
mM of ENU was adequate to induce 70% killing (Chapter 3 – Figure 1).  
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Using this concentration of mutagen we performed upwards of 20 attempts to 
generate parasite lines resistant to the parent compound (MMV006169), OSSL_324342 
(IC50=0.58 µM), OSSL_732641 (IC50=0.55 µM), and with OSSL_324373 (DBeQ, 
IC50=1.42 µM) (Chapter 2 – Table 3). These analogs were chosen based on potency. 
Despite changing the mutagenesis protocol, varying compound concentrations, and long-
term culturing in compound, we were unable to generate resistant parasite lines to any 
compound other than MMV006169. We isolated nine clones with some level of 
resistance to MMV006169, and saw a maximum shift in IC50 of 3.6-fold above the non-
mutagenized control (Clone 3, 4.41 µM, Chapter 3 – Table 1). However, we noted that 
these resistant parasites were never able to naturally egress from host cells. Instead, they 
stained positively with Dolichos biflorus lectin indicative of tissue cyst formation 
(Chapter 3 – Figure 2). This suggests that prolonged exposure to compound or the 
mutations created during ENU exposure resulted in differentiation into bradyzoites. 
Based on the lack of a robust shift in IC50 and the knowledge that other groups have been 
unable to isolate resistant mutants against related analogs (Jon Boyle, personal 
correspondence), we decided to implement an alternate strategy for target identification. 
 
3.3.2 Yeast three-hybrid system optimization 
As an alternate approach to identifying the target(s) of MMV006169, we 
performed library-scale yeast three-hybrid experiments to examine its target profile. As 
false-positives are a common constraint in yeast three-hybrid experiments, we 
implemented a negative selection step to minimize these interactions (Chapter 1 – Figure 
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5). We used the yeast strain BAPJ69-4A, which was generated such that the reporter 
URA3 was inserted into the HO locus under the control of a GAL4 inducible promoter, 
and media containing 5-fluoroorotic acid (5-FOA) for this selection (Chidley et al. 2011, 
Shaffer et al. 2012). In yeast without functional URA3, which encodes OMP 
decarboxylase, 5-FOA is converted to 5-fluorooritidine monophosphate (5-FOMP), 
which is not harmful to the cell. However, in the presence of functional OMP 
decarboxylase, 5-FOMP is converted to 5-fluorouridine monophosphate, a competitive 
inhibitor of thymidylate synthase, and is thus toxic to the cell. This means that anything 
expressing URA3 in the absence of a functional transcription factor will be killed. Yeast 
that survives this selection is pooled and used in conjunction with CID to perform our 
full-scale library screens.  
Titering of 3-amino-1, 2, 4-triazole (3-AT) also proved important in our library 
screens. 3-AT is a competitive inhibitor of the HIS3 gene, which encodes 
imidazoleglycerol-phosphate dehydratase. The HIS3 reporter has been shown to be leaky, 
meaning that low levels of the gene product are expressed in the absence of CID (Van 
Criekinge and Beyaert 1999). To counter this leakiness, 3-AT can be added to kill 
anything expressing low levels of HIS3 (Durfee et al. 1993, Fields 1993, Clontech 2007). 
We spread concentrations of 3-AT ranging from 0.31 µM – 5 µM and either DMSO or a 
positive control CID7 onto each plate. Library-containing yeast was then plated and the 
number of yeast colonies present on each plate was recorded daily for seven days 
(Chapter 3 – Table 2). We chose to use 3-AT at 1.25 µM, which inhibited background 
growth (DMSO plates) but allowed growth of yeast in the presence of CID.  
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3.3.3 A host cell target for MMV006169 
Screening of the negatively selected cDNA library with Mtx-MMV006169 
presented 18 clones encoding a potential CID-interacting protein. Each clone was 
analyzed in a reporter activation assay, where yeast growth is dependent on its ability to 
synthesize histidine. We isolated a single clone (#14) capable of growing robustly in 
media lacking histidine (Chapter 3 – Figure 3). Sequencing analysis revealed that this 
clone contained the C-terminal 867 base pairs of the gene encoding human NADH 
dehydrogenase subunit 2 (ND2; accession: P03891). ND2 is a component of complex 1 
of the electron transport chain, which plays a role in oxidation of NADH to NAD, proton 
pumping, and the shuttling of electrons to ubiquinone (Kerscher et al. 2008). It has been 
previously shown that both quinolones and quinazolines can inhibit complex 1 function, 
but inhibition is typically toxic to the host cell (Degli Esposti 1998, Li et al. 2003). Our 
initial analysis of toxicity at 24 hours showed no evidence of host cell toxicity (Chapter 2 
– Figure 4), however, upon extension of our toxicity analysis we found EN01.065 is toxic 
to host cells after longer periods of exposure (Chapter 3 – Figure 4).  This suggests that 
EN01.065 may be working by inhibiting ATP production.  
In contrast to the proton-pumping NADH dehydrogenase (complex 1) found in 
mammalian cells, T. gondii has 2 isoforms of type II, non-proton pumping NADH 
dehydrogenases (TgNDH2-1 and TgNDH2-2) (Saleh et al. 2007). It has been previously 
shown that HDQ, a quinolone, can directly inhibit TgNDH2-1 resulting in a defect in 
parasite replication (Lin et al. 2008). Since it is known that both quinolones and 
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quinazolines can inhibit mammalian complex I, we hypothesized that quinazolines may 
also be able to inhibit T. gondii NADH dehydrogenases. To test this, we cloned both 
isoforms (TgNDH2-1 and TgNDH2-2) into our yeast expression vectors and performed 
targeted yeast three-hybrid experiments using Mtx-MMV006169. Neither isoform 
resulted in reporter activation in this system, suggesting that MMV006169 does not 
interact with TgNDH2-1 or TgNDH2-2, but may actually be working through host cell 
ND2 (Chapter 3 – Figure 5). 
 
3.4 Discussion 
Small molecule target identification has been performed using a broad range of 
approaches, including affinity chromatography, phage-display libraries, whole genome 
mutagenesis, and yeast three-hybrid experiments (see Chapter 1 for comprehensive 
review). We recently screened the Medicines for Malaria Venture Open Access Malaria 
box (Chapter 2) (Bessoff et al. 2014). In that work, we show that MMV006169 is a 
potent inhibitor of T. gondii growth, more specifically invasion and replication.  In this 
study, we present the results of T. gondii whole genome mutagenesis to attempt to 
identify the target(s) of MMV006169. We attempted to generate mutants against 
MMV006169 and three structural analogs (OSSL_324342, OSSL_732641, and 
OSSL_324373), both at the IC50 and EC90 of each compound as determined by YFP-
based growth assay (see Chapter 2 for further detail). We were only able to generate 
mutants resistant to MMV006169 at its EC90 (3.2 µM). Of the 9 clones isolated, only a 
maximum of 3.6-fold increase in the IC50 of MMV006169 was observed. Previous work 
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with other compounds has shown that resistance is not always associated with large 
changes in the IC50. For example, Morrissette et al. isolated several different mutations in 
α-tubulin that conferred oryzalin resistance, but were associated with different changes in 
the IC50 (2 µM or 25 µM) compared with the original IC50 of oryzalin (Morrissette et al. 
2004). The same phenomenon was reported by Nagamune et al. who saw a 2 to 3-fold 
increases in the IC50 of artemisinin in resistant parasites compared to wild-type 
(Nagamune et al. 2007). However, the fact that we also could not generate mutants 
resistant to additional structural analogs, and the failure of other labs to do so (Jon Boyle, 
personal correspondance), led us to suspect that the molecule has more than one parasite 
target or it is working exclusively on host cells.  The former hypothesis is supported by 
the fact that structural analogs of MMV006169 show varying effects on T. gondii 
invasion and replication (Chapter 2). Additionally, work on a related analog 
(resynthesized and screened as FT14.116.2, Chapter 2 – Table 3) shows C5 inhibits T. 
gondii motility, but not invasion (Kamau et al. 2012), further suggesting the likelihood of 
the analogs hitting multiple targets.  
In this chapter, we presented preliminary data suggesting that an MMV006169-
resistant parasite line differentiates into bradyzoites when grown in the presence of 
compound. Since the genome of these parasites was never sequenced, we cannot confirm 
that they contained any point mutations rendering them truly resistant. This implies that 
treating tachyzoites with MMV006169 for prolonged periods of time results in their 
differentiation to bradyzoites. It is known that parasites will undergo differentiation as 
part of a stress repsonse when exposed to different pharmacological and physical triggers 
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(Sullivan and Jeffers 2012). Interestingly, it has also been shown that bradyzoites 
continue to replicate within tissue cysts at a rate much slower than tachyzoites (Watts et 
al. 2015). This led us to wonder if the parasites quantified in our replication assays were, 
in fact, bradyzoites and not tachyzoites. To test for a heightened stress reponse we can 
expose parasites to media of varying alkalinity (7.2-8.2) and look for differences in their 
ability to differentiate (Hong et al. 2016). If MMV006169 does cause a heightened stress 
response, compound exposure at pH 8.2 will result in a greater level of differentiation 
compared to untreated parasites. The same may hold true for lower pH (7.4 or 7.8) media, 
which doesn’t normally stimulate differentiation of wild-type parasites. Determination of 
the exact step in which stage conversion occurs will be the subject of future studies. 
In an attempt to identify the target(s) of MMV006169, we implemented a yeast 
three-hybrid approach, with which we have been successful in the past (Odell et al. 
2015). Our screening attempts suggest that MMV006169 may function by inhibiting 
human NADH dehydrogenase subunit 2 (ND2), a critical part of complex 1 of the 
electron transport chain.  Complex 1 is comprised of 46 different subunits, 7 of which 
(ND1-6 and ND4L) are mitochondrially encoded (Chomyn et al. 1985, Attardi et al. 
1986, Chomyn et al. 1986, Voet et al. 2008). The complex is divided into three functional 
units, a dehydrogenase, hydrogenase-like, and transport unit (Friedrich and Scheide 2000, 
Mathiesen and Hagerhall 2002). ND2 is part of the dehydrogenase unit, responsible for  
oxidizing NADH to NAD. ND2 is also thought to be necessary for proper complex 1 
assembly (Ugalde et al. 2007).  ND2 is comprised of 9 transmenbrane domains, 5 of 
which were present in the fragment recovered in our yeast three-hybrid screen. Typically, 
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transmembrane domain containing proteins are not recovered in yeast three-hybrid 
screens as they must be present in the yeast nucleus for an interaction to occur. However, 
since we are expressing only a fragment of a human gene in yeast, we cannot eliminate 
the possibility that the protein is misfolding or not being properly trafficked. The 
misfolded/improperly trafficked protein would be retained in the endoplasmic reticulum, 
and since the endoplasmic reticulum is contiguous with the nucleus these proteins could 
still interact with a CID.  
Over 60 different compound families have been shown to inhibit complex 1. 
They are divided into three different classes: A) quinones, B) semiquinones, and C) 
quinols (Degli Esposti 1998). Interestingly, no specific binding sites have been defined 
for these compound classes; they are all believed to bind the same hydrophobic pocket 
(Okun et al. 1999). MMV006169 contains a 2,4-diaminoquinazoline scaffold, which 
belongs with the class B inhibitors of ND2. Interesting, Mtx-MMV006169 was designed 
using EN01.065, an analog differing from the parent only in the addition of a methoxy 
group, as a starting point. EN01.065 shows the most dramatic impact on host cell ATP 
levels after 8 days, which further strengthens the hypothesis that MMV006169 analogs 
may work by inhibiting host cell enzymes.  
T. gondii isoforms of ND2 (TgNDH2-1 and TgNDH2-1) are considered 
alternative type II dehydrogenases. Their active sites face the mitochondrial matrix and 
they are individually non-essential (Lin et al. 2011). Like P. falciparum and most other 
type II NADH dehydrogenases, TgNDH2-1 and 2-2 are thought to interact with 
membranes through the aid of amphipathic α-helices, but possess no transmembrane 
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domains (Melo et al. 2004, Fisher et al. 2007, Lin et al. 2011). Individual deletions of 
either isoform result in replication defects (Lin et al. 2011) as does treatment of parasites 
with the TgNDH2-1 inhibitor 1-Hydroxy-2-Dodecyl-4(1H)Quinolone (HDQ).  Since 
treatment with MMV006169 matches the phenotype seen with HDQ, and the compounds 
both fit class B inhibitors of human ND2, we tested the hypothesis that MMV006169 
inhibits TgNDH2-1 and/or TgNDH2-2, but saw no positive interactions with either 
isoform by yeast three-hybrid. Taken together, these experiments suggest that 
MMV006169 may be working primarily through interactions with host cell NADH 
dehydrogenase, although we cannot eliminate the possibility that attaching a linker to 
MMV006169 prevents it from interacting from another relevant target. 
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Chapter 3 – Table 1: IC50 values for MMV006169 resistant parasite clones 
 
IC50 values extrapolated from YFP-based growth assays performed on MMV006169 
resistant clones. Clones were continuously cultured in 1% DMEM containing 3 µM 
(EC90) MMV006169. To conserve compound, clones were only assayed until a clean IC50 
curve was obtained with clones 1, 2, 8, and 9 being screened once, clones 3, 4, 6, and 7 
screened twice, and non-mutagenized screened in triplicate. Clone 5 did not recover after 
freeze thaw. 
 
Clone	#	 IC50	(μM)	
1	 3.35	
2	 2.13	
3	 4.41	
4	 3.39	
6	 4.06	
7	 1.80	
8	 3.42	
9	 2.30	
Non-mutagenized	 1.22	
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Chapter 3 – Table 2: Titering 3-AT 
 
3-AT was plated at the concentration indicated onto SC + Glu – trp – leu media. One 
hour later, CID7 (5 µM, A) or DMSO (B) were spread onto each plate. The next day, 
7x107 yeast cells were plated, plates were parafilmed and stored at 30°C for 7 days. The 
number of colonies per plate was recorded daily. 
 
A)
5.00 2.50 1.25 0.63 0.31 0.00
0 0 0 0 0 0 0
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 6
4 0 0 2 4 0 7
5 0 3 3 9 13 12
6 0 4 5 24 41 41
7 2 5 10 37 64 lawn
B)
5.00 2.50 1.25 0.63 0.31 0.00
0 0 0 0 0 0 0
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0
4 0 0 0 0 0 0
5 1 0 0 9 11 lawn
6 2 0 0 24 22 lawn
7 2 0 0 47 38 lawn
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Chapter 3 – Table 3: Primers for cloning T. gondii NDH2-1 and NDH2-2 
 
All primers were synthesized by Sigma Aldrich (The Woodlands, TX) with no special 
modifications. Sequences homologous to pGADT7 are underlined and were used for 
cloning in yeast. 
 
Primer Name Sequence (5'è3'); Sequence homolgous to pGADT7 is underlined 
14 NDH1IVCFw GAGTACCCATACGACGTACCAGATTACGCTATGGCAGGGCAGTGGCTGCG
15 NDH1IVCRev ACAAGCCGACAACCTTGATTGGAGACTTGATCACTTGCGTCGGTCGCCGT
16 NDH1-500Fw CGGAAGTTTCTACGAAGGC
17 NDH1-1000Fw GTCGACCTTTGCCTTCAGTC
18 NDH2IVCFw GAGTACCCATACGACGTACCAGATTACGCTATGGCGATGCTCTTCTCCAG
19 NDH2IVCRev ACAAGCCGACAACCTTGATTGGAGACTTGATCAGTGGTTGTAATATTCG
20 NDH2-500Fw CCGACACCTTGACCCAAAC
21 NDH2-1000Fw CAAAGAGGACATGAGCAAG
22 NDH2-1500Fw GGCCGACACGCACCGACCC
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Chapter 3 – Figure 1: Titration of ENU 
Plaque assay performed plating varying numbers of 2F1 YFP2 parasites (indicated left) 
exposed to varying concentrations of ENU (indicated bottom). Below is the standard 
survival curve for percent parasite survival versus concentration of ENU. Optimal 
concentration of ENU determined to be 6.31 mM. 
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DMSO	 MMV006169	
 
 
 
 
Chapter 3 – Figure 2: MMV006169 resistant clone forms cysts after compound 
treatment 
2F1 YFP2 parasites were continuously cultured in 1% DMEM containing 3 µM 
MMV006169 for seven days prior to fixation (3 µM corresponds to the EC90 with non-
mutagenized parasites).  DMSO control parasites were fixed after 24 hours. The cyst wall 
was stained with TRITC-conjugated Dolichos biflorus lectin and parasites with an anti-
Toxoplasma  antibody. 
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Chapter 3 – Figure 3: Clone 14 interacts with Mtx-MMV006169 
Targeted yeast three-hybrid assay where growth of yeast in media lacking histidine is a 
reflection of reporter activation. The positive control, CDPK1, is able to grow more 
robustly in the presence of CID7 than in DMSO (red versus blue bars), implying a direct 
interaction between CID7 and CDPK1. Clone #14 grows more robustly in the presence of 
Mtx-MMV006169 (purple, p≤0.05) than DMSO (green) suggesting the gene-product of 
clone #14 is a target of MMV006169. Bars represent mean +/- standard deviation; n=3. 
Data were analyzed using paired t-tests (*p≤0.05, **p≤0.01). 
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Chapter 3 – Figure 4: MMV006169 analog toxicity after 8 days 
Viability of host cells was determined via ATPase assay. HFFs were exposed to 10 µM 
analogs for 8-days prior to host cell lysis and quantification of ATP levels by 
luminescence. Luminescence is reported as relative luminescence units (RLU). All wells 
were normalized to a control with no CellTiter-Glo reagent. Sodium azide was included 
to represent a “kill control” in which we know the cells are no longer generating ATP.  
Bars represent mean +/- standard deviation, n=4. Data were analyzed using a one-way 
ANOVA (****p≤0.0001).  
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Chapter 3 – Figure 5: MMV006169 does not interact with TgNDHs by yeast three-
hybrid 
Targeted yeast three-hybrid experiments quantifying growth of yeast in media lacking 
histidine as a reflection of reporter activation. The positive control, BRADIN, is able to 
grow more robustly in the presence of CID7 than in DMSO (red versus blue bars), 
implying a direct interaction between the CID and TgBRADIN. NDH2-1 and NDH2-2 
grow to similar levels in the presence of Mtx-MMV006169 (purple) and DMSO (green), 
meaning the histidine reporter gene has not been activated. Bars represent mean +/- 
standard deviation; n=3. Data were analyzed using paired t-tests (****p≤0.0001). 
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
 
 Small molecule target identification is a lengthy process limited first by the 
identification of potent compounds of interest. Historically, large compound libraries 
have been screened with a low percentage of promising hits being identified (Carey et al. 
2004, Dittmar et al. 2016). It is impossible to know what the expected success rate of for 
target identification projects such as this should be, as most groups only document 
successes and not failures. It is even difficult to correlate successful target identification 
with compound potency. While it is true that increased potency may increase the 
specificity of a compound for its protein target(s), target identification has been 
successful using compounds with varying degrees of potency. For example, Compound 1 
was shown to specifically inhibit TgPKG with an IC50 1 nM (Donald et al. 2002), while 
atorvastatin inhibits the human quinone reductase, NQO2, with an IC50 of 50 µM  
(Chidley et al. 2011). This means that every target identification endeavor is unique and 
will come with its own set of challenges.  
Screening of the MMV Open Access Malaria box provided us with a novel 
starting point for compound discovery as the 400 compounds included in this collection 
were already shown to inhibit growth of the related apicomplexan, P. falciparum. 
Similarities between apicomplexans include a conserved intracellular life cycle involving 
invasion of host cells, modification of a parasitophorous vacuole, secretion from 
specialized organelles, and egress from host cells (Cowman and Crabb 2006, Boothroyd 
and Dubremetz 2008, Treeck et al. 2011). This study identified 79 inhibitors of T. gondii 
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growth, many of which were not identified in previous MMV box screens against T. 
gondii (Boyom et al. 2014). Boyom et al. reported 7 inhibitors of T. gondii growth with 
potencies ranging between 0.19-4.54 µM. Of these 11, only two, MMV666095 and 
MMV085203, were also found in our screen. The lack of overlap between MMV box 
screens could be a functional consequence of the screening assays chosen. The screen 
used by Boyom et al. involved incubation of parasites with compound for 24 hours 
followed by treatment with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) and the electron coupling reagent 
phenazine methosulfate (PMS). MTS is converted to formazan, which can be read at 490 
nm absorbance. This means our assay runs for 7 days longer, has 8 times as many time 
points, and is read based on fluorescence instead of absorbance. Of the 79 molecules we 
identified, MMV006169 was shown to be an inhibitor of replication and invasion with no 
quantifiable difference seen in two-dimensional motility.  
Our targeted yeast three-hybrid experiments using TgCDC48Cy and 
TgCDC48Ap were unsuccessful, however, they only included the genes cloned into the 
yeast vector such that the GAL4-AD was fused to the amino-terminus of each protein. It 
would be interesting to examine the effect of carboxy-terminal fusions. If these proteins 
generated a functional yeast three-hybrid complex, it would suggest the previous amino-
terminal fusion was preventing proper CID-target protein interaction. Both isoforms of 
TgCDC48 have been shown to retain localization upon carboxy-terminal tagging, but no 
attempts have been made to alter the amino terminus (Agrawal et al. 2009). Additionally, 
it is known that CDC48 associates with Der1, a pore involved in the ERAD pathway. It is 
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possible that CDC48 needs to be associated with this pore for proper folding or activity to 
occur. T. gondii has 3 isoforms (2 localized to the endoplasmic reticulum, 1 localized to 
the apicoplast) of the S. cerevisiae Der1, the most similar localizing to the endoplasmic 
reticulum and having 20% identity. Rather than using yeast three-hybrid, precursor 
molecules synthesized during CID generation can be immobilized to a column and used 
for affinity purification experiments with either recombinantly expressed CDC48 
isoforms in the presence and absence of Der1, or with whole parasite lysates to determine 
if the presence of Der1 reveals an active site for MMV006169 on CDC48.  
Interestingly, there is a third form of TgCDC48 (TgME49_230710) annotated in 
the Toxoplasma database (www.toxodb.org, release 29). This gene has never been 
studied, with very limited proteomics data available to confirm the suggested sequence. 
This isoform shares 17% identity with the S. cerevisiae CDC48, which is predicted to 
interact with DBeQ, 17% identity with TgCDC48Cy, and 19% identity with 
TgCDC48Ap. This lack of homology suggests that this third “isoform” of TgCDC48 will 
not interact with DBeQ, and thus also not MMV006169. However, it would be easy to 
assess this by cloning TgME49_230710 into our yeast expression vectors and performing 
targeted yeast three-hybrid analyses as previously described. 
Our library scale yeast three-hybrid experiments suggest that the target of 
MMV006169 may be the host cell mitochondrially-encoded NADH dehydrogenase 
subunit 2.  The fragment pulled from the library encodes 739 base pairs of ND2 
equivalent to 5 transmembrane domains. Yeast three-hybrid systems are notoriously poor 
at detecting transmembrane domain containing proteins, as they must be retained in the 
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nucleus to activate the expression of reporter genes. However, the system has worked in 
some cases to isolate transmembrane domain-containing proteins (Young and Ozenberger 
1995, Kajkowski et al. 1997). Since the fragment of ND2 isolated in our screen is 
typically encoded on the human mitochondrial genome, it does not contain a 
mitochondrial localization sequence. So, while the protein has transmembrane domains, it 
does not have a targeting sequence to shuttle it away from the endoplasmic reticulum 
after folding. Additionally, the yeast expression vector used in our experiments contains a 
nuclear localization sequence. That sequence in conjunction with the fact that the nucleus 
is contiguous with the endoplasmic reticulum might explain why this transmembrane 
domain containing protein was identified in our yeast three-hybrid experiments (Laba et 
al. 2014). However, it is equally likely that this interaction is the artifact of improper 
protein folding or the consequence of having expressed only a fragment of the protein. 
We can directly test the inhibition of ND2 by MMV006169 by performing a 
mitochondrial in vitro activity assay. This works by isolating mitochondria from lysed 
host cells with differential centrifugation. Mitochondria are solubilized with digitonin or 
maltocide and complex 1 is immunocaptured. Substrates are mixed with MMV006169 
and changes in NADH are measured spectrophotometrically (Janssen et al. 2007, 
Spinazzi et al. 2012). If NADH levels are reduced we will know that ND2 is a target of 
MMV006169.  
The same logic described above also pertains to the targeted yeast three-hybrid 
experiments performed with TgNDH2-1 and TgNDH2-2. Both were cloned as amino-
terminal fusions with the GAL4-AD. It would be interesting to see if the results of the 
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assay were to differ had the activation domain been fused in a different position. 
Additionally, it has been previously shown that TgNDH2-1 can be functionally expressed 
in Yarrowia lipolytica, which expresses a single, non-essential NDH2 and as such is the 
model organism for the study of alternative NADH dehydrogenases (Kerscher 2000). 
This model was used to confirm that TgNDH2-1 is the target of HDQ (Lin et al. 2008). It 
would be interesting to determine if MMV006169 works on TgNDH2-1 using the same 
system. It would also be useful to optimize the system such that TgNDH2-2 can be used. 
Initial attempts to express TgNDH2-2 in Y. lipolytica demonstrated oxidoreductase 
activity equivalent to that of having no dehydrogenase present (Lin et al. 2008). We 
suspect the primary reason for this is the improper identification of mature protein start 
positions. The T. gondii mitochondrial localization sequence is insufficient to target these 
isoforms to the Y. lipolytica mitochondria (Lin et al. 2008). To aid in this process, the 
mitochondrial NUAM protein localization sequence was fused to the predicted mature 
protein start site and full length start positions of each protein. For TgNDH2-1, only the 
fusion to the predicted mature start position allowed oxidoreductase activity (Lin et al. 
2008). By troubleshooting the mature protein start position of TgNDH2-2, we may be 
able to generate an enzyme that functions more efficiently in Y. lipolytica and as such can 
be used to directly test if MMV006169 can inhibit its activity.    
The most direct set of experiments to test the hypothesis that MMV006169 
interacts with TgNDHs would be to generate clean TgNDH2-1 and TgNDH2-2 gene 
deletions and look for a change in parasite sensitivity to compound. Proof of concept 
experiments have already been performed on parasites lacking these genes in the 
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presence of HDQ (Lin et al. 2011). Using CRISPR technology, we would individually 
delete each isoform of the NADH dehydrogenase and replace it with a selectable marker 
(Shen et al. 2014, Sidik et al. 2014). Upon confirmation of the proper genotype, we 
would perform replication assays (see Chapter 2 – Materials and Methods) and look for a 
change in the number of parasites present per vacuole. If we see an increase in the 
number of parasites per vacuole upon compound treatment in one (or both) knockout 
parasite lines, we will know that we have isolated a relevant target. If we do not, then 
TgNDHs do not interact with MMV006169. 
Throughout the course of this project a major problem has been trying to 
determine if we have identified an inhibitor of the parasite or host cell. While the above 
experiments are elegant and informative, they are also work and resource intensive. To 
easily distinguish between a host cell and parasite target, we could perform experiments 
where human ND2 activity is measured in the presence of MMV006169 as described 
above to determine if the compound has any impact on the host enzyme (Janssen et al. 
2007, Spinazzi et al. 2012). Measurements of parasite ATP levels would then be 
performed in the presence of MMV006169 and other known complex 1 inhibitors such as 
piercidin A and capsaicin to see if similar effects are noted on parasite ATP levels (Degli 
Esposti 1998, Carey et al. 2004). These experiments would quickly tell us if the genetic 
approaches described above would be worth pursuing.   
 The yeast strain used in this work, BAPJ69-4A, was chosen for the presence of 
the negatively selectable marker, URA3, and three additional reporters ADE2, HIS3, and 
lacZ under the control of galactose inducible promoters (Shaffer et al. 2012). We had 
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hoped that using this strain would allow us to significantly reduce the number of false 
positive clones obtained during screening to streamline the target identification process. 
However, while the negative selection did prevent a large number of yeast from growing 
on selective plates in the absence of CID, even our positive control experiments using 
TgBRADIN and TgCDPK1 resulted only in the activation of the histidine reporter in the 
presence of CID. This means that even with verified small molecule-protein interactions, 
three of the reporters in this strain were non-responsive. Since the arduous processes of 
SAR analysis and CID synthesis have already been completed, it would be interesting to 
screen different T. gondii cDNA libraries with these MMV006169-based CIDs to see 
what putative targets are identified. We currently have two different libraries in hand and 
several yeast strains that can be used with different reporters for testing CID-dependent 
reporter activation. Moreover, we have received a number of P. falciparum, P. yoelii, and 
P. vivax cDNA libraries (generous gifts of Drs. Douglas LaCount, Purdue University, and 
Lawrence Bergman, Drexel University), and we have synthesized our own C. parvum 
cDNA library. All of these libraries would be of interest to screen against our current 
CIDs. It would also be imperative to include human cDNA libraries in future screens to 
address the possibility that the compounds are binding to host cell targets. 
 While yeast three-hybrid approaches have been used successfully for target 
identification in T. gondii (Odell et al. 2015) and other systems (Licitra and Liu 1996, 
Chidley et al. 2011) the work presented here highlights some of the complications 
associated with the technology. The best possible cDNA library, most potent compound, 
and well-designed CID should be in place before attempting these experiments and even 
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then the target(s) of the compound of interest may not be identified. Amongst other 
reasons, this could be because (1) the phenotype in the initial screening assay is based on 
synergistic (multiple targets) effects of the compound, (2) the target is not present in the 
library, (3) the target is not properly folded or retained in the yeast nucleus, (4) or the 
target requires the presence of other proteins in a complex to maintain the conformation 
necessary to interact with the compound of interest. To increase the likelihood of success, 
multiple strategies for target identification should be used in parallel with yeast three-
hybrid. Here we attempted to perform whole genome mutagenesis to identify the target of 
MMV006169, but were unsuccessful likely because the molecule is specific for the host 
cell or has multiple targets.  
 The modular approach to CID synthesis developed by our collaborators could, in 
principle, facilitate the use of other target identification approaches (Tran et al. 2013). 
The intermediate molecules derivatized to some length of linker can be attached to biotin 
and as such immobilized to streptavidin-coated beads for affinity chromatography or 
phage display approaches. Alternatively, the precursor molecule could be labeled with a 
fluorophore for use in a drug western blot.  The recent advances in the field using 
CRISPR technology have simplified the follow-up required once a potential target has 
been identified (Shen et al. 2014, Sidik et al. 2014, Sidik et al. 2016). One can now 
determine if a gene is essential based on a literature search and then generate a gene 
deletion, disruption, or inducible down-regulation in one step. The resulting parasite line 
is then grown in the presence and absence of compound to confirm that the correct target 
was identified.    
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 This work has contributed to the field of apicomplexan biology by identifying a 
number of potent inhibitors of T. gondii growth that could be used as biological probes to 
better aid in the understanding of apicomplexan biology. More specifically, it has 
outlined SAR leading to the identification of a number of replication and invasion 
inhibitors of T. gondii. It has also contributed by further outlining strengths and 
weaknesses of a variety of approaches to small-molecule target identification.  
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APPENDIX A: ANALYSIS OF THE REPLICATION INHIBITOR MMV403679 
 
[N.B. Structural analogs synthesized for this work produced by Stephen Ojo (University 
of St. Andrews). C. parvum data presented here were generated by the joint effort of Kovi 
Bessoff and Rajiv Jumani (University of Vermont).] 
 
As mentioned in Chapter 2, our screens of the MMV Open Access Malaria box 
lead us to the identification of five small molecules of interest. MMV403679, is a potent, 
non-toxic inhibitor of both T. gondii and C. parvum growth (Appendix A – Figure 1; 
(Bessoff et al. 2014)). The compound also inhibits T. gondii replication (Appendix A – 
Figure 2). To better understand how MMV403679 inhibits T. gondii and C. parvum, we 
performed extensive structure-activity relationship analyses on this compound using 38 
analogs either purchased (Life Chemicals, Ontario, Canada) or synthesized (Appendix A 
– Table 1). We had aimed to use this SAR to develop a novel CID for use in yeast three-
hybrid experiments, but never reached that point with the project.  
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Appendix A – Table 1: MMV403679 structural analogs 
 
Thirty-eight structural analogs of MMV403679 containing a conserved allopurinol 
chemical scaffold. Calculated IC50 values for each analog and corresponding 95% 
confidence intervals are reported. Excessively wide confidence intervals are reported as 
“n/a”.  
 
Name Structure T. gondii IC50 (µM) T. gondii IC50 95% CI C. parvum IC50 (µM) C. parvum IC50 95% CI
F5091-0161 0.04 (0.03-0.05) 0.06 N/A
F5091-0196 0.04 (0.010-0.17) 0.12 (0.08-0.19)
F5091-0208 0.06 (0.05-0.06) 0.07 (0.06-0.09)
F5091-0573 0.06 N/A 0.18 N/A
F5091-0036 0.07 (0.06-0.08) 0.07 (0.04-0.10)
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F5091-0230 0.09 (0.04-0.19) 0.15 (0.11-0.21)
F5091-0270 0.10 (0.08-0.12) 0.12 (0.07-0.21)
F5091-0204 0.10 (0.06-0.15) 0.08 (0.07-0.09)
F5091-0186 0.10 very wide 0.04 (0.03-0.05)
F5091-0123 0.10 (0.07-0.15) 0.08 (0.06-0.10)
SA006 0.10 (0.08-0.13) Not screened Not screened
F5091-0869 0.11 (0.01-2.61) 0.17 N/A
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F5091-0273 0.13 (0.11-0.14) 0.12 (0.10-0.14)
SA001 0.14 (0.11-0.17) 1.4 (0.16-12.21)
SA010 0.14 (0.12-0.17) Not screened Not screened
F5091-0873 0.15 (0.11-0.21) 0.21 (0.10-0.45)
F5091-0723 0.18 (0.13-0.24) 0.41 (0.24-0.71)
SA004 0.21 (0.18-0.25) 1.17 (0.93-1.47)
F5091-0038 0.22 (0.17-0.30) 0.10 (0.07-0.16)
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SA013 0.25 (0.21-0.29) Not screened Not screened
Reordered 
F5091-0273 0.26 (0.22-0.31) Not screened Not screened
SA003 0.31 (0.21-0.45) 0.32 (0.26-0.39)
Synthesized 
403679 0.36 (0.30-0.45) 0.65 (0.60-0.71)
SA002 0.37 (0.24-0.58) 1.11 (0.94-1.31)
F5091-0871 ~ 0.3806 very wide 0.14 (0.09-0.24)
F5091-0080 0.44 (0.38-0.51) 0.57 (0.39-0.83)
 133 
F5091-0655 0.49 (0.39-0.60) 0.20 (0.16-0.25)
SA011 0.66 (0.56-0.76) Not screened Not screened
F5091-0772 1.24 (0.68-2.23) 0.20 (0.17-0.24)
F2135-0883 1.21 (0.86-1.22) 0.9992 (0.91-1.10)
403679-4 1.31 (1.08-1.59) 1.032 (0.81-1.32)
SA005 1.38 (1.17-1.63) 2.24 (1.94-2.58)
F5091-0249 1.61 (1.19-2.17) 0.17 (0.14-0.21)
 134 
SA009 2.41 (1.83-3.18) Not screened Not screened
SA007 3.13 (2.84-3.44) Not screened Not screened
F5091-0127 4.57 (3.65-5.72) 0.69 (0.53-0.90)
SA016 >18.18 N/A Not screened Not screened
403679-1 >18.18 N/A >10 N/A
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Appendix A – Figure 1: MMV403679 is not toxic to human foreskin fibroblasts 
Viability of host cells was determined using the Promega CellTiter-Glo ATPase assay per 
manufacturer’s instructions (see Chapter 2 Materials and Methods). HFFs were exposed 
to 10 µM MMV403679 for 24-hours followed by lysis of host cells and quantification of 
ATP levels by luminescence. Luminescence is reported as relative luminescence units 
(RLU). All samples were normalized to a control of HFFs and media with no CellTiter-
Glo reagent. Sodium azide (N3Na) was included as a control for host cell death where 
cells are no longer generating ATP.  Bars represent mean +/- standard deviation, n=3. 
Data were analyzed using a one-way ANOVA (***p≤0.001).  
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Appendix A – Figure 2: MMV403679 inhibits T. gondii replication 
Human foreskin fibroblasts were infected with 2F1 YFP2 strain T. gondii and grown in 
the presence (green) or absence (blue) of 1 µM MMV403679 for 12, 24, or 36 hours. The 
average number of parasites per vacuole at each time point was determined by 
immunofluorescence (n=3, ***p ≤ 0.001, **** p ≤ 0.0001 as determined by two-way 
ANOVA). 
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APPENDIX B: ATTEMPTS TO IDENTIFY THE TARGET(S) OF QQ-437 
 
[N.B. Structural analogs synthesized for this work were produced by Fanny Tran 
(University of St. Andrews).] 
 
QQ-437 is a highly potent compound that has previously been shown to reduce 
T. gondii proliferation. Insertional mutagenesis has provided indirect evidence that the 
target of QQ-437 is adaptin 3-beta (AP3B) (Fomovska et al. 2012). We attempted to 
confirm this hypothesis by cloning TgAP3B into the yeast three-hybrid vector pGADT7 
and have used two different QQ-437-based chemical inducers of dimerization (CIDs) 
(Appendix B – Figure 1) to screen for an interaction between QQ-437 and AP3B. These 
CIDs were synthesized based on data generated in a small-scale SAR screen (Appendix B 
– Table 1). Unfortunately, there was not a positive interaction between either of our CIDs 
and AP3B (Appendix B – Figure 2). This may be due to insufficient SAR leading to 
suboptimal positioning of linker attachment or because AP3B is not the biologically 
relevant target of QQ-437 in T. gondii. To test the latter hypothesis, I have screened both 
CIDs against our T. gondii cDNA library and was unable to isolate any true interactions 
via yeast three-hybrid.  
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Appendix B – Table 1: QQ-437 structural analogs 
 
Structures of QQ-437 and 11 structural analogs. Calculated IC50 values for each analog 
and corresponding 95% confidence intervals are reported. Excessively wide confidence 
intervals are reported as “n/a”.  
 
Name Structure T. gondii IC50 (uM) T. gondii IC50 95% CI
FT07.134.1 0.00009324 (0.00005-0.00015)
QQ437 0.004053 (0.002-0.006)
FT07.131.8a 0.005604 (0.004-0.007)
FT14.009.3 0.01622 (0.01-0.03)
FT07.168.3 0.07419 (0.06-0.10)
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FT07.135.8 0.1591 (0.12-0.20)
QQ437-Azide 0.2764 (0.24-0.31)
FT07.059.3 0.3971 (0.20-0.79)
FT14.028.3 2.269 (2.09-2.47)
FT07.067.3 >18.18 N/A
FT07.068 >18.18 N/A
FT07.070.3 >18.18 N/A
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Appendix B – Figure 1: Structures of QQ-437-based CIDs 
A) Structure of QQ437CID1. B) Structure of QQ437CID2. QQ-437 structure is 
highlighted in pink, linker in green, and methotrexate is shown in blue.  
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Appendix B – Figure 2: Targeted yeast three-hybrid suggests QQ-437 does not 
interact with AP3B. 
Growth of yeast in media lacking histidine is a reflection of reporter activation. The 
positive control, pGADBRADIN, is able to grow more robustly in the presence of CID7 
than in DMSO (red versus blue bars), implying an interaction between CID7 and 
BRADIN. pGADAP3B grows to the same level in the presence of (A, purple) 
QQ437CID1, (B, purple) QQ437CID2, and DMSO (green), meaning no reporter 
activation is seen. Bars represent mean +/- standard deviation; n=3. Data were analyzed 
using paired t-tests (****p≤0.0001). 
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APPENDIX C: SCREENING A SUBSET OF THE NIH CLINICAL 
COLLECTION 
 
[N.B. The full NIH Clinical Collection screening against C. parvum and selection of this 
subset of molecules was performed by Kovi Bessoff (University of Vermont)] 
 
As part of an effort to identify novel inhibitors of T. gondii growth, we received a 
subset of compounds taken from the NIH Clinical Collection (NCC) for screening. The 
NCC is comprised of 719 FDA-approved small molecules, classified as both drug and 
drug-like, with known mechanisms of action. Our collaborators screened the entire 
collection against the related apicomplexan C. parvum and a subset of molecules that 
showed inhibitory activity were provided for screening against T. gondii (Bessoff et al. 
2013). Using the previously described YFP-based growth assay (Chapter 2 Materials and 
Methods) these compounds were screened in triplicate (Appendix C – Figure 1). The 
majority of the compounds inhibited T. gondii growth with sub-micromolar potency, and 
many of them have known targets in human cells or are likely working through inhibition 
of DNA replication. We aimed to determine if these compounds inhibit T. gondii in a 
manner similar to that of host cells. This would help identify conserved pathways and 
thus aid in the understanding of general parasite biology. Moreover, if compounds were 
found to work differently, they could be used to tease apart parasite biological 
mechanisms.  
 
 143 
Appendix C – Table 1: Efficacy of NIH Clinical Collection compounds on T. gondii 
growth.  
 
YFP-based growth assays were performed on 17 NCC compounds as previously 
described. Each compound was serially diluted to yield a total of 11 test concentrations 
that were screened in triplicate.  
 
 T. gondii IC50 (μM) T. gondii IC50 95% CI Homoharringtonine 0.03029 0.02048 to 0.04479 
Docetaxel 0.03855 0.02866 to 0.05184 
Digoxin 0.07251 0.06177 to 0.08512 
Hexachlorophene 0.09068 0.06052 to 0.1359 
Triptolide 0.1309 Very Wide 
Minocycline 0.2278 0.09084 to 0.5713 
5-Fluorouracil 0.2343 0.1968 to 0.2791 
Oligomycin C 0.396 0.2277 to 0.6887 
Floxuridine 0.4183 0.1770 to 0.9885 
Chloroxine 0.5631 0.2798 to 1.133 
Carmofur 0.8335 0.4586 to 1.515 
Indomethacin 1.234 0.7927 to 1.920 
Doxycycline 1.311 0.6706 to 2.565 
Tegaserod Maelate 5.301 3.552 to 7.910 
6-Azauridine >18uM N/A 
Glipizide >18uM N/A 
Mevastatin >18uM N/A 
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APPENDIX D: TARGETED YEAST THREE-HYBRID FOR INTERACTION 
BETWEEN 118793 AND EG5 
 
During the original small-molecule screen performed in our lab, 118793 was 
identified as one of the more potent inhibitors of T. gondii invasion (Carey et al. 2004). In 
mammalian cells it has been shown that 118793 interacts with the mitotic kinesin Eg5 
(Hotha et al. 2003). Preliminary structure-activity relationship (SAR) data suggest that 
the target in T. gondii is not likely a homolog of this mammalian protein. However, 
mammalian Eg5 represents an excellent positive control for drug-protein interaction 
studies involving 118793. To develop this positive control, we amplified full-length 
mammalian Eg5 from cDNA generated from human foreskin fibroblasts (HFFs) and 
cloned it into the yeast vector pGADT7. The resulting plasmid was then co-transformed 
into AH109 with pGBKeDHFR and used in targeted yeast three-hybrid experiments 
(Chapter 2 Materials and Methods) with the previously generated CIDs 2 (ST501611) 
and 3 (ST504011) at varying concentrations. At that point in our development of the 
yeast three-hybrid system, there was no positive control to use in these assays, so they 
were performed only with the addition of a DMSO control. No reporter activation was 
seen upon the addition of either CID (Appendix D – Figure 1). Without a positive control 
we cannot conclude that 118793 cannot interact with Eg5, but these experiments obtained 
negative results.  
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Appendix D – Figure 1: Targeted yeast three-hybrid suggests Eg5 does not 
interact with 118793. 
Growth of yeast in media lacking adenine is a reflection of reporter activation. 
PGADFLEg5-containing yeast grows to the same level in the presence of CID2 (1 and 10 
µM, red and green), CID 3 (1 and 10 µM, purple and orange), and DMSO (green), 
meaning no reporter activation occurred. Bars represent mean +/- standard deviation; 
n=3. Data were analyzed using paired t-tests. 
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APPENDIX E: GENERATING THE TgUNC ANTIBODY AND DEFINING 
CELLULAR LOCALIZATION 
 
[N.B. The rabbit work including antigen injections and bleeds were done by Cocalico 
Biologicals (Stevens, PA). Testing of antibody against Sf9 cell samples was performed by 
Anne Kelsen (University of Vermont).] 
 
TgUNC, a UCS-domain containing protein, has been shown to aid in TgMyoA 
folding, but the protein itself has never been characterized in T. gondii (Bookwalter et al. 
2014). UCS-domain containing proteins historically interact with myosins and heat shock 
proteins and are found in many different organisms including a number of apicomplexan 
parasites. First attempts to characterize the gene involved localizing it in intact parasites. 
Using both FLAG- and 3xMyc-tagged TgUNC (RH ΔhxgprtΔku80) it was determined 
that the protein localizes in a punctate manner to the parasite cytosol (Appendix E – 
Figure 1).  
To further characterize the protein, we attempted to generate a TgUNC antibody. 
The UCS domain (last 1327bp) of TgUNC was sub-cloned into pCR 2.1-Topo vector 
using TA cloning. The resulting plasmid was digested with HindIII and NdeI to excise 
the UCS domain. The 1.3kb fragment was then ligated into pre-digested (HindIII/NdeI) 
pET28a and sequenced to ensure proper insertion and the plasmid was renamed 
pETUCSDCln1. pETUCSDCln1 was transformed into BL21-CodonPlus(DE3)-RIL 
competent cells for bacterial expression. A negative control of pET28a transformed into 
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BL21-CodonPlus(DE3)-RIL competent cells was included in parallel in all induction 
experiments. A single colony of bacteria was used to inoculate 3 mL of LB supplemented 
with 50µg/mL kanamycin and incubated overnight at 37°C. The next day, the culture was 
diluted 1:20 and grown with shaking at 37°C for 2 hours. Uninduced samples (1 mL 
each) were removed and prepared for analysis on an SDS-PAGE gel. The remaining 
culture was induced by adding 1 mM IPTG and incubated with shaking at 37°C for 2 
hours. Whole cell lysate samples were removed and prepared for loading on an SDS-
PAGE gel. The remaining cells were pelleted, frozen, thawed, and resuspended in B-PER 
Bacterial Protein Extraction Reagent mixed with lysozyme and DNAse. The large bands 
shown between 37 and 50 kDa show the bacterially expressed UCS domain (Appendix E 
– Figure 2, white box). These bands are notably absent from the empty vector control.  
Ten pre-bleed samples were provided by Cocalico Biologicals (22-31) for 
examination. Western blots were performed on T. gondii RH lysate using pre-bleed anti-
sera as primary antibody (1:500 and 1:2000) and goat anti-rabbit (1:20000) as secondary 
antibody (Appendix E – Figure 3).  Anti-sera 30 and 31 were only screened at 1:500 due 
to lack of space on the SDS-PAGE gel. Pre-bleed anti-sera 24, 29, 30, and 31 were 
eliminated from further study due to excessive cross-reactivity between the anti-sera and 
RH lysate. Anti-sera samples 22, 23, 25, 26, 27, and 28 were screened by 
immunofluorescence to confirm lack of reactivity against T. gondii (Appendix E – Figure 
4). From this subset, rabbits 22 and 26 (renamed UVT149 and UVT150 by Cocalico 
Biologicals) were injected with UCSD (UCS domain only) antigen to generate 
antibodies. Subsequent bleeds from each animal were screened by western blot for 
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reactivity against RH ΔhxgprtΔku80, 3xMYC- (UCS3xMYCCln1), or FLAG-tagged 
(UCSFLAGCln4) TgUNC lysates to confirm that TgUNC could be detected (Appendix E 
– Figure 5). UVT150 appears to be the stronger antibody by western blot, while UVT149 
is stronger by immunofluorescence based on co-localization with 3xMYC-tagged 
parasites (Appendix E – Figure 6). Additionally, UVT150 was screened against 
baculovirus/Sf9 recombinantly expressed full-length TgUNC (FL TgUNC), TgUNC 
lacking the TRP domain (ΔTPR), and the UCS-domain (UCS only) of TgUNC alone 
(Bookwalter et al. 2014). All recombinantly expressed proteins were detected using 
UVT150 (Appendix E – Figure 7).  
In addition to the generation of an antibody, parasites lacking TgUNC were 
generated using the DiCre system (Andenmatten et al. 2012). The conditional deletion 
will circumvent the potential issue of protein compensation, where a related protein takes 
the place of TgUNC. It also allows us to look at the phenotypic consequences of the gene 
deletion if TgUNC is essential. The DiCre system requires the use of MG311 parasites, 
which are RH ΔhxgprtΔku80 strain parasites with multiple copies of dimerizable Cre 
recombinase randomly integrated into the genome. To use this strain, 3xMYC-tagged 
TgUNC was cloned into pG265, between two loxP sites. The 5’ and 3’UTRs were also 
cloned into the vector to ensure proper targeting to the TgUNC locus. The resulting 
parasites were selected in 50 µg/mL xanthine and 25 µg/mL mycophenolic acid. To 
induce gene excision, parasites were incubated in 50 nM rapamycin for 3 hours followed 
by syringe release and plating on a fresh monolayer of HFFs. After 48 hours, parasite 
lysate was prepared. Evidence in the field suggests that a deletion of TgUNC results in 
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the loss of TgMyoA (along with all other myosins) (Graindorge et al. 2015). To confirm 
the excision of TgUNC, a quantitative western blot for TgMyoA normalized to GRA8 
was performed. The addition of rapamycin resulted in the depletion of TgMyoA in two 
independent clones (D3 and D6), with no loss of signal seen in the non-loxP flanked 
3xMYCUCSCln1 (Appendix E – Figure 8). 
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Appendix E – Figure 1: Subcellular localization of TgUNC  
3xMYC-tagged TgUNC localizes to the T. gondii cytosol (red, top). DeltaVision 
deconvolution microscopy (bottom) shows that TgUNC has a punctate arrangement in 
the cytosol. A TgGAP45 antibody was used to outline the entire tachyzoite (green). 
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Lane	 Sample	
1	 UCSD	Induced	Whole	Cell	Lysate	
2	 UCSD	Uninduced	Whole	Cell	Lysate	
3	 UCSD	Induced	Soluble	Frac<on	
4	 UCSD	Uninduced	Soluble	Frac<on	
5	 UCSD	Induced	Insoluble	Frac<on	
6	 UCSD	Induced	Insoluble	Frac<on	Diluted	1:1	
7	 UCSD	Uninduced	Insoluble	Frac<on	
8	 UCSD	Uninduced	Insoluble	Frac<on	Diluted	1:1	
9	 Empty	Vector	Induced	Whole	Cell	Lysate	
10	 Empty	Vector	Uninduced	Whole	Cell	Lysate	
11	 Empty	Vector	Induced	Soluble	Frac<on	
12	 Empty	Vector	Uninduced	Soluble	Frac<on	
13	 Empty	Vector	Induced	Insoluble	Frac<on	
14	 Empty	Vector	Induced	Insoluble	Frac<on	Diluted	1:1	
15	 Empty	Vector	Uninduced	Insoluble	Frac<on	
16	 Empty	Vector	Uninduced	Insoluble	Frac<on	Diluted	1:1	
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Appendix E – Figure 2: IPTG Induction of TgUNC UCS domain expression.  
Induced and uninduced samples of BL21 bacteria containing pETUCSDCln1. Bacterially 
expressed UCSD is highlighted between 50 and 37 kDa in the induced insoluble fraction 
(white box, lanes 5 and 6), but is notably absent from the uninduced samples (lanes 13 
and 14).  
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Appendix E – Figure 3: Screening pre-bleed samples against RH lysate  
T. gondii RH lysate (equivalent of ½ of a T175 flask in large vacuoles) was run on small 
SDS-PAGE gel. Samples were probed using indicated pre-bleed at 1:500 and 1:2000 
overnight (except 30 and 31, 1:500 only), followed by secondary probing with goat anti-
rabbit antibody (1:20000). Robust cross-reactivity seen in pre-bleeds 24, 29, 30, and 31 
resulted in their discontinuation from consideration for antibody generation. 
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Appendix E – Figure 4: Immunofluorescence with pre-bleeds against T. gondii  
RH strain T. gondii was probed with each pre-bleed (1:500) followed by goat anti-rabbit 
antibody (1:500). Pre-bleeds showing parasite fluorescence (23, 25, 27, and 28) were 
eliminated from further consideration.  
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Appendix E – Figure 5: Western blot against T. gondii lysates using UVT149 and 
UVT150 
RH ΔhxgprtΔku80, 3x-MYC-, and FLAG-tagged TgUNC parasite lines were probed with 
UVT149 and UVT150 bleeds at 1:500 (6 boosts, 070114) followed by goat anti-rabbit 
antibody (1:20000). UVT149 does not show reactivity with antibody, while UVT150 
shows specificity in all three parasite lines (white box).  
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Appendix E – Figure 6: Immunofluorescence of UCS3xMYCCln1 parasites using 
UVT149 and UVT150 
3x-MYC-tagged parasites were stained with UVT149 and UVT150 bleeds at 1:500 
(terminal bleed, 102014) followed by goat anti-rabbit antibody (1:500). UVT149 (top, 
green) staining co-localizes with anti-MYC staining (red), while UVT150 appears non-
specific (bottom, green).   
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Appendix E – Figure 7: Western blot against recombinantly expressed TgUNC  
(full-length and truncations) using UVT150 
Baculovirus/Sf9 recombinantly expressed full-length TgUNC (FL TgUNC), TgUNC 
lacking the TRP domain (ΔTPR), and the UCS-domain (UCS only) of TgUNC probed 
with UVT150 terminal bleed. All recombinantly expressed forms of TgUNC are detected 
by UVT150, with little cross-reactivity in the cells only control.  
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Appendix E – Figure 8: Inducible knock-out of TgUNC results in loss of TgMyoA 
Quantified western blot of non-loxP flanked 3xMYC-tagged TgUNC (C13) versus loxP 
flanked 3xMYC-tagged TgUNC expressing parasites with and without rapamycin 
(TgMyoA=100 kDa, TgGRA8=38 kDa, n=1). 
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APPENDIX F: DRUG AFFINITY RESPONSIVE TARGET STABILITY AS AN 
APPROACH TO TARGET IDENTIFICATION 
 
[N.B. Baculovirus expressing recombinant TgMLC1 was generated by Jacqueline Leung 
(University of Vermont).] 
 
Drug affinity responsive target stability (DARTS) is a genomics-based approach 
to target identification. The approach is based on the assumption that the binding of a 
small molecule/drug of interest to a target protein may stabilize that protein’s structure in 
such a way as to make it less susceptible to proteolysis (Lomenick et al. 2009, Lomenick 
et al. 2011, Pai et al. 2015). DARTS was chosen because it allows one to analyze lower 
affinity reactions that are typically lost using other techniques, it requires no chemical 
modification or derivatization of the target protein or small molecules, and can be used 
with any cell or tissue type. TachypleginA binds covalently to TgMLC1 and upon 
binding results in an electrophoretic mobility shift associated with the formation of a 
225.118 Da adduct on the protein (Heaslip et al. 2010, Leung et al. 2014). This pair 
presented a unique way to visually troubleshoot DARTS, as unbound, unmodified 
TgMLC1 should be degraded while the bound form should remain intact (Appendix F – 
Figure 2B). The assay was performed using Sf9 cell extracts made using PBS 
supplemented with small amounts of CaCl2 and a concentration of subtilisin between 5-
10 ng per 10 µL of extract. It was found that the addition of TachypleginA to 
recombinant TgMLC1 did not protect the protein from proteolysis (Appendix F – Figure 
 159 
2A). This is demonstrated by the disappearance of both the upper and lower bands in 
each TachypleginA treated sample. The same results were obtained using an alternate 
protease (pronase). This technique has been unsuccessful thus far in our hands and needs 
further optimization.  
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Appendix F – Figure 1: Schematic of DARTS mechanism 
Lysate or extract is prepared and incubated with the small molecule/drug of interest (or 
vehicle control). The protease of choice is then added to each sample and incubated for a 
pre-optimized amount of time. Samples are prepared for running on SDS-PAGE gel 
followed by western blot or staining to visualize proteolysis.  
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Appendix F – Figure 2: DARTS using TgMLC1 and TachypleginA 
A) DARTS using whole cell lysate. Sf9 cells expressing recombinant Myosin Light 
Chain-1 were harvested and treated with 40mM TachypleginA or equivalent volume of 
DMSO. Samples were subjected to subtilisin digestion, run on an SDS-PAGE gel, and 
analyzed via western blot with an anti-MLC1 antibody. B) Predicted DARTS outcome 
for recombinant TgMLC1 protected by TachypleginA. 
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APPENDIX G: DETERMING IF TgBRADIN CAN INTERACT WITH p38α 
MAP KINASE 
 
[N.B. Appendix G – Figure 1 was generated by Gary Ward (University of Vermont).] 
 
While our paper discussing TgBRADIN as a target of Compound 2 was under 
revision, another group published an analysis of TgBRADIN (which they named GRA24) 
(Braun et al. 2013, Odell et al. 2015). TgBRADIN/GRA24 was shown to be secreted by 
the parasite into the host cell cytosol where it associates with p38α MAP kinase (p38α 
MAPK). This presented us with the hypothesis that TgBRADIN/GRA24 interacts 
indirectly with Compound 2 through p38α MAPK. To directly test this an 
immunoprecipitation of the entire yeast three-hybrid complex (Appendix G – Figure 1) 
was attempted, where protein G beads and an anti-HA antibody were used to pull-down 
the HA-tagged c-terminal portion of TgBRADIN (Screen 3 Hit#4). If an interaction is 
occurring one would be able to detect TgBRADIN, p38α MAPK, and LexA in the 
presence of Mtx-Cmpd2.1. Additionally, immunoprecipitation with free Compound 2 
(C2) should result in the disappearance of TgBRADIN. Standard western blots were 
performed and it was determined that both p38 and LexA were detectable in whole cell 
lysates, but only LexA was found in immunoprecipitations with (bound) or without 
Compound 2 competition. Both p38 and LexA were absent from the eluate collected after 
Compound 2 competition (Appendix G – Figure 2A). Upon striping and re-probing the 
blot, it was determined that TgBRADIN was found in all samples except the eluate 
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(Appendix G – Figure 2B). Taken together, these data suggest that TgBRADIN is not 
interacting with Compound 2 through p38α MAPK.  
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Appendix G – Figure 1: Hypothesized role of p38α MAPK in yeast three-hybrid 
complex  
Yeast three-hybrid schematic where p38α MAPK (yellow) acts as a bridging protein 
between compound 2 (blue) containing CID (MTX-Cmpd2.1) and TgBRADIN (red). The 
methotrexate moiety of MTX-Cmpd2.1 (green) interacts with the DNA-binding domain 
(DBD, purple). The activation of reporter genes occurs upon interaction of the quaternary 
complex.  
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Appendix G – Figure 2: p38α MAPK is not present in yeast three-hybrid complex 
Yeast containing the functional TgBRADIN yeast three-hybrid complex were grown to 
log phase in the presence of CID. HA-tagged TgBRADIN was immunoprecipitated (IP) 
using protein G beads and an anti-HA antibody. The resulting IP was run on an SDS-
PAGE gel including whole cell lysate, IP with and without compound 2 competition, and 
the eluate isolated from the compound 2 competition. The gel was prepared for western 
blot and probed for A) p38α MAPK (green) and LexA-DHFR (red) and B) HA-
TgBRADIN (green) and LexA-DHFR (red). * Indicates cross reactivity with heavy 
chain. 
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APPENDIX H: USING 3-DIMENSIONAL MOTILITY ASSAYS TO EXAMINE 
THE ROLE OF CALCIUM IN T. GONDII MOVEMENT 
 
It has been shown that calcium is involved in parasite motility, conoid extension, 
microneme secretion, invasion, and egress (Carruthers et al. 1999, Carruthers and Sibley 
1999, Lovett and Sibley 2003, Wetzel et al. 2004, Del Carmen et al. 2009, Borges-Pereira 
et al. 2015). However, the spatial and temporal dynamics of calcium fluctuations are 
unclear. For these experiments, we used a microscopic assay, first developed in our 
laboratory, which tracks parasites as they move in a three-dimensional matrix (Leung et 
al. 2014). We expanded on this powerful assay by using T. gondii parasites transfected 
with genetically encoded calcium indicators (i.e., GCaMPs) (Borges-Pereira et al. 2015) 
to track changes in calcium concentration as parasites move (Appendix H – Figure 1). 
This allows us to measure changes in intracellular calcium concurrently with velocity 
(Appendix H – Figure 2), displacement, twist, acceleration, and curvature with the 
objective of determining if there is a correlation between calcium fluctuation and any of 
these parameters. We have optimized the assay with respect to matrigel 
concentrations/batches, intensity of light, imaging time, heating conditions, and image 
interpretation methods. Using this optimized system, we have generated preliminary data 
suggesting that there is an increase in parasite calcium levels prior to increases in parasite 
speed (Appendix H – Figure 1 and Figure 2 *). Using the results of the aforementioned 
experiments, we have performed experiments using small molecules known to alter 
calcium oscillations in the parasites. We used caffeine, which has been shown to lengthen 
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calcium oscillations, calmidazolium, which shortens the oscillations (Wetzel et al. 2004), 
and thapsigargin, which can cause shallow rapid or long slow oscillations (Nagamune et 
al. 2007). These experiments have been completed in triplicate and have been run 
through the existing analysis software (designed to analyze velocity, curvature, torsion, 
and acceleration) generated with the help of Mark Rould, but no notable phenotypes were 
seen with respect to log KS values (Leung et al. 2014). Log KS values represent the 
statistical Kolmogorov–Smirnov test. This test is used to show variation both within 
(same treatment and parasite line) and between (different treatments and/or parasite lines) 
data sets. In these experiments, we noted a lot of variability within datasets, meaning that 
DMSO-treated samples of the same parasite line did not behave in the same manner 
across biological replicates. As such we cannot conclude that large variation in the data 
are due to compound treatment and not just day-to-day variation. Work is currently 
underway to modify the existing software such that it is capable of developing a spatially 
and temporally resolved model of calcium levels in moving parasites.  
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Appendix H – Figure 1: Increases in calcium precede increases in velocity along 
parasite trajectories 
Visualization of calcium levels (intensity sum, left) and velocities (right) along two 
parasite trajectories (A and B).  
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Appendix H – Figure 2: Oscillations in intracellular parasite calcium levels during 
motility 
Graphical representation of simultaneous measurements of intracellular calcium level 
(blue) and speed (red) of GCaMP6-expressing parasites as they move through Matrigel. * 
Indicates a pane where a spike in calcium can be seen before an increase in speed across 
the majority of the graph. 
 
